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ABSTRACT

Olanzapine, a second generation antipsychotic drug, is widely used to treat multiple
domains of schizophrenia and other mental disorders. However, it is associated with
substantial body weight gain/obesity side-effects. Since the antagonistic affinity to
histaminergic H1 receptor (H1R) has been identified as a major contributor for
antipsychotic-induced weight gain, this thesis investigated the effects and mechanisms
of co-treatment with betahistine (a histaminergic H1R agonist and H3 receptor
antagonist) for ameliorating olanzapine-induced weight gain/obesity in a series of four
experiments using a female rat model.

The first experiment showed that short-term (2 weeks) combination treatment of
betahistine and olanzapine (O+B) reduced (-45%) body weight gain and feeding
efficiency caused by olanzapine in drug-naïve rats. Olanzapine significantly upregulated
expressions of H1R, Neuropeptide Y (NPY), and AMP-activated protein kinase ɑ
(AMPKɑ) phosphorylation, that were reversed by O+B co-treatment. Hypothalamic
pro-opiomelanocortin (POMC) expression was decreased by olanzapine, but not
affected by O+B co-treatment. These results suggest that O+B co-treatment may reduce
olanzapine-induced weight gain via the H1R-NPY and H1R-pAMPKɑ pathways.

Since patients suffering with schizophrenia and other mental disorders often face
chronic, even life-time, antipsychotic treatment, I further investigated effects of chronic
O+B co-treatment on preventing olanzapine-induced weight gain. Chronic coadministration of O+B significantly reduced (-51.4%) weight gain, feeding efficiency,
liver and fat mass induced by olanzapine. Consistently, the chronic olanzapine-only
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treatment increased expressions of hypothalamic H1R, pAMPKɑ and NPY, while
reducing uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor
gamma coactivator1-alpha (PGC-1a) levels in brown adipose tissue. These olanzapineinduced changes could be reversed by chronic O+B co-treatment.

Following experiments investigated the effects of O+B co-treatment on the primary
therapeutic receptor binding sites of olanzapine in various brain regions. Both shortterm olanzapine-only and O+B co-treatment significantly decreased 5-HT2A receptor (5HT2AR) bindings in the prefrontal cortex (PFC), cingulate cortex (Cg), and nucleus
accumbens (NAc), but had no effects on dopamine D2 receptors (D2R). Olanzapine also
significantly decreased 5-HTT bindings in the ventral tegmental area (VTA) and
substantia nigra (SN). The results confirmed the important role of 5-HT2AR in the
efficacy of olanzapine, which was not influenced by short-term O+B co-treatment.

Both chronic olanzapine-only and O+B co-treatment significantly decreased the
bindings of 5-HT2AR, 5-HT2CR, and 5-HTT in the PFC, Cg and NAc. The chronic
olanzapine-only treatment significantly increased the D2R bindings in the Cg, NAc, and
CPu (which might be attributed to “dopaminergic supersensitivity”), while the chronic
betahistine-only treatment reduced D2R bindings. Chronic O+B co-treatment reversed
the D2R bindings in the NAc and CPu that were increased by chronic olanzapine
treatment. Therefore, chronic O+B co-treatment has similar effects on serotonin
neurotransmission as olanzapine-only treatment, but reverses the D2R binding that is
upregulated by chronic olanzapine treatment.
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In brief, this thesis provided sound evidence that both short-term and chronic cotreatment with betahistine would be effective combination therapy to reduce olanzapineinduced weight gain without affecting its therapeutic effects. These results support
further clinical trials to test the effectiveness of betahistine co-treatment for controlling
weight gain/obesity side-effects in schizophrenia patients with antipsychotic treatment.
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CHAPTER 1
GENERAL INTRODUCTION

Schizophrenia is a devastating mental disorder influencing functions of the central
nervous system (van Os and Kapur, 2009). As one of the first line second generation
antipsychotic drugs (SGAs), olanzapine is widely used to treat multiple domains of
schizophrenia symptoms and other serious mental disorders (Meltzer, 2013). However,
it is associated with substantial body weight gain/obesity and other troublesome
metabolic side-effects such as type II diabetes and cardiovascular disease (Coccurello
and Moles, 2010; Deng, 2013). The antagonistic affinity to histaminergic H1 receptor
(H1R) of SGAs has been identified as one of the main contributors to weight
gain/obesity side-effects, suggesting H1R as a potential target for controlling SGAinduced weight gain side-effects (Dwyer et al., 2005; Deng et al., 2010). Therefore, this
thesis investigated the effects and mechanisms of co-treatment with betahistine (a
histaminergic H1R agonist and H3 receptor antagonist) for ameliorating olanzapineinduced weight gain/obesity in a female rat model.

The study in Chapter 3 showed that a short-term (2 weeks) combination treatment of
betahistine (2.67 mg/kg, t.i.d.) and olanzapine (1 mg/kg, t.i.d.) (O+B) reduced (-45%)
body weight gain induced by olanzapine in drug-naïve rats. To reveal the mechanisms
underlying these effects, a number of experiments were performed to investigate the
effects of co-treatment of O+B on the expressions of H1R, AMP-activated protein
kinase (AMPK), neuropeptide Y (NPY), and proopiomelanocortin (POMC) in the
hypothalamus associated with reducing olanzapine-induced weight gain. Olanzapine
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significantly upregulated mRNA and protein expressions of H1R, while O+B cotreatment significantly downregulated H1R levels, compared to the olanzapine-only
treatment group. NPY mRNA expression was significantly enhanced by olanzapine, but
it was significantly reversed by O+B co-treatment. Hypothalamic H1R expression was
positively correlated with total food intake, and NPY expression. Olanzapine also
increased

AMPKɑ

activation

measured

by

the

AMPKɑ

phosphorylation

(pAMPKɑ)/AMPKɑ ratio compared with controls, whereas O+B co-treatment
decreased the pAMPKɑ/AMPKɑ ratio, compared with olanzapine only treatment. The
pAMPKɑ/AMPKɑ ratio was positively correlated with total food intake and H1R
expression. Although olanzapine administration decreased the POMC mRNA level, this
level was not affected by O+B co-treatment. Therefore, these results suggested that cotreatment (2 weeks) with betahistine may reverse olanzapine-induced body weight gain
via the H1R-NPY and H1R-pAMPKɑ pathways.

Another key issue is that clinical patients suffering with schizophrenia, bipolar disease
and other mental disorders often face chronic, even life-time, antipsychotic treatment, in
which they have often had previous antipsychotic exposure (Maayan et al., 2010).
Therefore, in Chapter 4, we investigated the effects of chronic (5 weeks) O+B cotreatment in controlling body weight in female rats with chronic and repeated exposure
to olanzapine. Rats were treated with olanzapine (1 mg/kg, t.i.d.) or vehicle for 3.5
weeks, and then olanzapine treatment was withdrawn for 19 days. From week 6, the two
groups were divided into 4 groups (n=12) for 5 weeks’ treatment: (1) olanzapine-only (1
mg/kg, t.i.d.), (2) betahistine-only (9.6 mg/kg, t.i.d.), (3) olanzapine and betahistine cotreatment (O+B), and (4) vehicle. The results showed that 5 weeks co-administration of
O+B significantly reduced (-51.4%) weight gain induced by olanzapine. Co-treatment
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of O+B also led to a decrease in feeding efficiency, liver and fat mass. Consistently, the
olanzapine-only treatment increased hypothalamic H1R protein levels, as well as
hypothalamic pAMPKɑ, AMPKɑ and NPY protein levels, while reducing hypothalamic
POMC, and uncoupling protein 1 (UCP1) and peroxisome proliferator-activated
receptor gamma coactivator1-alpha (PGC-1a) protein levels in brown adipose tissue
(BAT). The olanzapine induced changes in hypothalamic H1R, pAMPKɑ, BAT UCP1
and PGC-1a could be reversed by co-treatment of O+B. These results supported further
clinical trials to test the effectiveness of co-treatment of O+B for controlling weight
gain/obesity side-effects in schizophrenia with chronic antipsychotic treatment.

The study presented in Chapter 5 investigated the effects of short-term (2 weeks) cotreatment of O+B on the primary therapeutic receptor binding sites of olanzapine
(Meltzer, 2013), that are serotonergic 5-HT2A receptor (5-HT2AR), 5-HT transporter (5HTT) and dopaminergic D2 receptor (D2R) bindings in various brain regions involved in
antipsychotic efficacy including the prefrontal cortex (PFC), cingulate cortex (Cg),
nucleus accumbens (NAc), and caudate putamen (CPu) (using samples from Chapter 3
experiments). Quantitative autoradiography was used to detect the density of
[3H]ketanserin, [3H]paroxetine and [3H]raclopride binding sites to 5-HT2AR, 5-HTT and
D2R. Compared to the controls, olanzapine significantly decreased [3H]ketanserin
bindings to 5-HT2AR in the PFC, Cg, and NAc. Similar changes in 5-HT2AR bindings in
these nuclei were also observed in the O+B co-treatment group. Olanzapine also
significantly decreased [3H]paroxetine binding to 5-HTT in the ventral tegmental area
(VTA) and substantia nigra (SN), however, neither olanzapine only nor O+B cotreatment affected [3H]raclopride binding to D2R. The results confirmed the important
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role of 5-HT2AR in the efficacy of olanzapine, which is not influenced by O+B cotreatment.

The study in Chapter 6 investigated the effects of chronic (5 weeks) treatment of
olanzapine and/or betahistine on the binding density of serotonergic 5-HT2AR and 5HT2CR, 5-HTT, and dopaminergic D2R in the PFC, Cg, NAc, and CPu. Compared to the
control, the olanzapine-only treatment significantly decreased the bindings of 5-HT2AR,
5-HT2CR, and 5-HTT in the PFC, Cg and NAc. Similar changes were observed in the
rats receiving the O+B co-treatment. The olanzapine-only treatment significantly
increased the D2R binding in the Cg, NAc, and CPu, while the betahistine-only
treatment reduced D2R binding. Co-treatment with betahistine reversed the D2R
bindings in the NAc and CPu that were increased by olanzapine. Therefore, chronic
O+B co-treatment has similar effects on serotonin neurotransmission as the olanzapineonly treatment, but reverses the D2R that is upregulated by chronic olanzapine treatment.

To sum up, this thesis systematically revealed the mechanisms of co-treatment with
betahistine in reducing olanzapine-induced body weight gain via modulation of the
hypothalamic H1R-AMPKɑ, NPY, and BAT UCP1-PGC-1α pathways. Understanding
the mechanisms of betahistine in the prevention and treatment of olanzapine-induced
obesity through these signalling pathways will potentially lead to a new treatment
strategy for schizophrenia with the development of more effective antipsychotic drugs
with fewer side-effects. On the other hand, in both short-term/drug-naïve and
chronic/drug-repeated treatment subjects, because both olanzapine-only and O+B cotreatment have similar effects in attenuating 5-HT2AR, 5-HT2CR and 5-HTT levels,
betahistine may be safely co-administered with olanzapine without influencing
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olanzapine’s therapeutic action on serotonin neurotransmission. Additionally, since
chronic olanzapine treatment with betahistine can reverse the elevated D2R binding
caused by chronic olanzapine treatment, co-treatment with betahistine may improve
therapeutic effects by preventing the “dopaminergic supersensitivity” caused by chronic
antipsychotic treatment. These results provided solid evidence supporting further
clinical trials in treating antipsychotics-induced weight gain using betahistine in patients
with schizophrenia and other mental disorders.
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CHAPTER 2
LITERATURE REVIEW

2.1 Introduction
Schizophrenia remains a chronic, severe and complicated psychotic disorder impairing
the function of the central nervous system (CNS), and is one of the most costly diseases
to sufferers and their families (Tandon et al., 2008; van Os and Kapur, 2009). Broadly,
it is characterised by positive symptoms (such as delusions, hallucinations), negative
symptoms (such as apathy, avolition and poverty of speech), as well as cognitive
deficits (such as deficits in memory, attention and executive function) (van Os and
Kapur, 2009). The onset of the disorder is normally during late adolescence or early
adulthood (Laruelle et al., 2003; Robinson et al., 2004), with a world-wide prevalence
of 1-2% in the general population (McGrath et al., 2003; Perala et al., 2007). The
significant medical co-morbidity and mortality of schizophrenia may shorten the
average life-span by 10-30 years (Goff et al., 2005). It is believed that factors such as
genetics and environmental vulnerability can affect multiple neurotransmitter systems,
such as the dopaminergic, glutamatergic and muscarinic systems, which cause
schizophrenia (Lieberman, 2006; Deng and Dean, 2013). In order to attenuate the
symptoms of schizophrenia, pharmacological interventions, psychosocial rehabilitation
and nutritional supplements have been supplied (Kohler et al., 2014). To date,
pharmacological intervention using antipsychotic drugs plays the most critical role in
schizophrenia treatment. Unfortunately, current antipsychotic drugs have limited
efficacy for treating this complex disease (Meltzer, 2013), but cause some serious sideeffects (Deng, 2013; Werner and Covenas, 2014).
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Antipsychotic drugs have brought a significant improvement in the treatment of
schizophrenia since the 1950s, and other psychiatric disorders, and can be broadly
classified into two generations. First generation antipsychotic drugs (FGAs), also called
“typical antipsychotics”, such as chlorpromazine and haloperidol, can ameliorate the
positive symptoms such as delusions and hallucinations although they are less effective
on the negative symptoms such as apathy, avolition, and cognitive deficits of
schizophrenia. Indeed, FGAs work mostly by blocking the dopaminergic D2 receptor
(D2R) (Seeman, 2011; Ginovart and Kapur, 2012). However, D2R blockade by FGAs
also causes extra-pyramidal symptoms (EPS) side-effects, such as tardive dyskinesia
and akathisia, as well as hyperprolactinemia and body weight gain to some extent,
which is problematic for long-term use (Bishara and Taylor, 2008). For example,
clinical studies demonstrated that 1 year of haloperidol treatment in first-episode
patients led to a substantial weight gain side-effects (between 7.3 and 9.56 kg) (Kahn et
al., 2008; Perez-Iglesias et al., 2008), although haloperidol was originally believed to
have far fewer body weight gain side-effects compared with second generation
antipsychotics (Bobes et al., 2003b; Tardy et al., 2014).

Second generation antipsychotic drugs (SGAs), also called “atypical antipsychotics”,
such as olanzapine and clozapine currently form the first line of treatment for
schizophrenia and other serious mental disorders, and are effective to some degree in
relieving the positive and negative symptoms, as well as cognitive deficits of
schizophrenia, with fewer EPS side-effects at clinically effective doses (Kane and
Correll, 2010; Lambert, 2011; Meltzer, 2013). Interestingly, meta-analysis showed that
SGAs are not a homogeneous class of drugs and are associated with distinct efficacy
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and side-effects profiles (Leucht et al., 2009; Kane and Correll, 2010). The
pharmacological properties of SGAs are predominantly potent as a serotonergic 5-HT2A
receptor (5-HT2AR) antagonist, and dopaminergic D2R antagonist, as well as, in some
cases such as aripiprazole, as D2R and 5-HT1A receptor (5-HT1AR) partial agonists
(DeLeon et al., 2004). SGAs normally cause serious metabolic side-effects, especially
weight gain and obesity. Among the SGAs, olanzapine and clozapine are associated
with the most severe weight gain/obesity side-effects, and with other prominent
metabolic diseases such as dyslipidaemia, gluco-regulatory abnormalities and insulin
resistance, and type II diabetes (Milano et al., 2013), and are currently of great interest
to clinicians due to their widespread use in clinics (Correll et al., 2011; Osuntokun et al.,
2011). More importantly, these side-effects are associated with relapse of psychosis due
to non-compliance, increased morbidity and mortality, as well as reduced quality of life
(Lieberman et al., 2005; Spelman et al., 2007). However, to date, there is no effective
way to prevent or treat SGA-induced weight gain/obesity side-effects.

Accumulated evidence has demonstrated that antipsychotics effects encompass a wide
range of non-dopaminergic G-protein-coupled receptors including histaminergic H1
(H1R), serotonergic 5-HT2C (5-HT2CR), and muscarinic M3 (M3R) receptors,
contributing to weight gain/obesity side-effects (Harris et al., 2013) (Table 2.1). Among
them, H1R antagonism has been identified as one main indicator for predicting weight
gain-induced by SGAs (Kroeze et al., 2003; Deng et al., 2010). As a potential target for
treating weight gain side-effects, therefore, this PhD study investigated whether cotreatment with betahistine (an H1R agonist and H3 receptor (H3R) antagonist) can
ameliorate olanzapine-induced weight gain, and also elucidated the underlying
mechanisms, using the established animal models. Furthermore, it has also detected
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whether co-treatment with betahistine affects the key receptor binding sites (e.g. 5HT2AR and D2R) involved in the therapeutic effects of olanzapine.

2.2 Literature Review
2.2.1 Neuropharmacological mechanisms of therapeutic efficacy of antipsychotics
SGAs, including olanzapine and clozapine, have a pharmacological profile with various
antagonistic and/or agonistic binding affinities with various neurotransmitter receptors
such as serotonergic (5-hydroxytryptamine, 5-HT), dopaminergic, muscarinic,
adrenergic and histaminergic receptors, which may play a significant role in their
therapeutic efficacy and side-effects (Fulton and Goa, 1997; Meltzer, 1999; Milano et
al., 2013; Urs et al., 2014) (Table 2.1). It has been proposed that the interaction between
5-HT and dopamine systems, also called the “serotonin-dopamine hypothesis”, plays a
significant role in the therapeutic action of SGAs, in that most SGAs such as olanzapine
have greater affinity for 5-HT2A (5-HT2AR) compared with dopamine D2 (D2R)
receptors (Kuroki et al., 2008; Meltzer and Massey, 2011). On the other hand, 5-HT2CR,
histaminergic H1 receptor (H1R) and muscarinic M3R have been reported to be involved
in SGA-induced weight gain and other metabolic side-effects (Deng et al., 2010; Correll
et al., 2011; Roerig et al., 2011).
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Table 2.1 Weight gain and receptor binding affinities for antipsychotics.

Receptor

Haloperidol

Clozapine

Olanzapine

Quetiapine

Risperidone

Aripiprazole

5-HT2C

10,000

17

6.8

2,502

35

22.4

5-HT2A

53

5.4

2

101

0.17

8.7

D2

4

256

34

245

6.5

0.66

H1

1,800

1.2

2

11

15

29.7

H3

>10,000

6,357

3,713

>10,000

>10,000

>10,000

M3

10,000

25

105

10,000

10,000

4,677

α1A

12

1.64

115

22

5

26

α2A

1,130

142

314.1

3,630

150.8

74

Weight
Gain
(kg/10wks)

0.48

4.00

3.51

2.61

1.67

0.71

The receptor affinity values were reported as Ki (nM). 5-HT2C, serotonin2C; 5-HT2A,
serotonin2A; α1A, adrenergic α1A; α2A, adrenergic α2A; D2, dopamine2; H1, histamine1; M3,
muscarinic3. (Data adapted from Allison et al., 1999, Kroeze et al., 2003). For
histamine3 (H3) receptors, Ki determination was generously provided by the National
Institute of Mental Health's Psychoactive Drug Screening Program, Contract #
NO1MH32004 (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth MD,
PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie
Driscol at NIMH, Bethesda MD, USA.
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2.2.1.1 The role of dopamine neurotransmission in antipsychotic efficacy
From the 1960s, abnormal dopaminergic signalling has been recognised as a key
contributor in the pathophysiology of schizophrenia (van Rossum, 1966). It was
reported in the 1970s that utilizing competition binding experiments with
[3H]haloperidol and [3H]dopamine, the property of all antipsychotics was attributed to
their ability to bind with dopamine receptors in striatal homogenates (Creese et al.,
1976; Seeman et al., 1976). The “dopamine hypothesis of schizophrenia” supposed the
hyperactivity of dopaminergic neurotransmission at D2R, which was proven in both
clinic and animal models via examining the ability of dopamine agonist, amphetamine,
in stimulating dopamine release (Miyamoto et al., 2003; Tenn et al., 2003).

There are four major dopaminergic neuron projections that are derived from the
mesencephalon: 1) the mesolimbic pathway, dopaminergic neurons projecting from the
ventral tegmental area (VTA) to the nucleus accumbens (NAc), which is related to the
positive symptoms of schizophrenia; 2) the mesocortical pathway, dopaminergic
neurons projecting from the VTA to the frontal cortex including the prefrontal cortex
(PFC) and cingulate cortex (Cg), which is associated with the negative symptoms and
cognitive deficits of schizophrenia; 3) the nigrostriatal pathway, dopaminergic neurons
projecting from the substantia nigra (SN) to the caudate putamen (CPu), which is
involved in motor control; and 4) the tuberoinfundibular pathway, dopaminergic
neurons projecting from the hypothalamus to the pituitary gland, which is associated
with hyperprolactinaemia side-effects of FGAs (Ginovart and Kapur, 2012; Russo and
Nestler, 2013).
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Dopaminergic D2Rs are also expressed at the presynaptic level as autoreceptors that
regulate the synthesis and release of dopamine, as well as the firing of dopamine
neurons (Ginovart and Kapur, 2012). It has been revealed that D2R performs its
physiological function throughout both G-protein-dependent and independent (the
scaffolding protein β-arrestin 2-dependent) signalling (Beaulieu et al., 2005; Miyamoto
et al., 2012). D2R occupancy plays a critical role in predicting antipsychotic responses
and side-effects, which has been supported using PET (positron emission tomography)
and SPECT (single photon emission computed tomography) (Remington and Kapur,
1999; Seeman, 2011; Ginovart and Kapur, 2012). It was demonstrated that for FGAs,
antipsychotic efficacy requires 65-70% D2R occupancy, while the >80% D2R
occupancy significantly increased the risk of EPS side-effects (Remington and Kapur,
1999).

Although SGAs target multiple receptors (particularly 5-HT2R) and have reduced EPS
side-effects (but cause serious metabolic disorders), some authors suggested that their
antagonistic action at the dopaminergic D2R was sufficient for antipsychotic activity
(Tarazi et al., 2001; Ginovart and Kapur, 2012). It has been indicated that chronic/subchronic administration of haloperidol (an FGA), as well as olanzapine and clozapine
(SGAs), induce upregulation of D2R binding levels and dopamine release in the PFC,
NAc, CPu and hippocampus (O'Dell et al., 1990). However, short-term SGA treatment
often revealed no alteration in D2R levels (Kusumi et al., 2000). Another theory
suggested that some SGAs including aripiprazole have faster dissociation rates (koff
values), while other SGAs including olanzapine and risperidone have slower
dissociation from the D2R (Seeman, 2002). As a partial D2R agonist, aripiprazole has
lower D2R affinity compared with full agonists, which inhibits endogenous dopamine
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activity and prevents excessive D2R activation (Han et al., 2009; Ginovart and Kapur,
2012; Miyamoto et al., 2012). However, SGAs such as clozapine and quetiapine
exhibited less striatal D2R occupancy (<60%) compared to FGAs, which indicated that
besides the D2R blockade, other neurotransmission systems may also be involved in the
therapeutic efficacy of SGAs such as olanzapine and clozapine (Ginovart and Kapur,
2012; Miyamoto et al., 2012).

2.2.1.2 The role of serotonin neurotransmission in therapeutic efficacy of SGAs
Besides the vital role of the dopamine system in the pathological theory and treatment
of schizophrenia, over the past decades greater attention has been paid to other
neurotransmissions including the serotonergic system (Matsumoto et al., 2005; Meltzer,
2012). The serotonergic system is believed to modulate numerous sensory, motor and
behavioural processes in the mammalian nervous system, and is also implicated in the
pathology of schizophrenia and other mental disorders such as depression and bipolar
disorder (Carlsson, 1987; Tecott et al., 1995; Davis and Chen, 2001; Sawa and Snyder,
2002; Carlsson et al., 2004; Dolzan et al., 2008). The serotonin (5-HT) is one of major
monoaminergic neurotransmitters in the brain, and acts through 5-HT receptors,
including the 5-HT1A-F, 5-HT2A-C and 5-HT3-7 receptor subtypes (Meltzer et al., 2003).
Among them, the 5-HT2A, 5-HT2C, 5-HT3, 5-HT6 and 5-HT7 receptors are associated
with the therapeutic efficacy of SGAs (Meltzer and Huang, 2008).

SGAs such as olanzapine, clozapine, quetiapine, risperidone, and ziprasidone treat
schizophrenia through direct or indirect effects on distinct 5-HT receptors (Meltzer et al.,
2003; Meltzer, 2007). In particular, as shown in Table 2.1, the 5-HT2AR and 5-HT2CR
are G-protein-coupled receptors involved in the therapeutic effects of SGAs including
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olanzapine and clozapine (Horacek et al., 2006; Meltzer, 2012). However, it has also
been reported that clozapine and risperidone, but not olanzapine, significantly enhanced
extracellular 5-HT release in the NAc and PFC, which contribute to the SGAs’ affinity
in improving mood disorders and cognition (Ichikawa et al., 1998).

In addition, the 5-HT neurons originating from the raphe nuclei of the midbrain,
innervate both the SN and VTA, in which there exist higher densities of 5-HT immunereactive fibres connecting synaptically with both dopamine and non-dopamine neurons
(Di Matteo et al., 2001). In particular, it was reported that 5-HT2AR, 5-HT1AR and 5HT2CR contributed to serotonergic modulation, which can enhance dopamine output in
the striatum and PFC (Horacek et al., 2006). Therefore, another explanation regarding
the therapeutic efficacy of SGAs is the interaction between the 5-HT and dopamine
receptors (Meltzer, 2012).

A. The role of 5-HT2AR in therapeutic efficacy of SGAs
Serotonergic 5-HT2AR is widely expressed throughout the CNS, particularly in most of
the serotonergic terminal rich areas, including the PFC, NAc, and in the cell bodies of
dopamine neurons in the VTA and SN, as well as in most cortical pyramidal neurons
(Jakab and Goldman-Rakic, 1998; Doherty and Pickel, 2000). The 5-HT2AR is a Gprotein-coupled receptor linked to the intracellular molecular signal-transduction
cascade, which plays a crucial role in the therapeutic action of SGAs and psychiatric
disorders (Kusumi et al., 2000; Horacek et al., 2006; Meltzer and Massey, 2011). The
accumulated evidence has demonstrated that SGAs such as olanzapine and clozapine
attenuate 5-HT2AR binding and mRNA expression (which are involved in the
therapeutic effects of SGAs) in the PFC, NAc, Cg, and SN after both acute and chronic
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administration (Kusumi et al., 2000; Kuroki et al., 2003; Huang et al., 2006b; Kuroki et
al., 2008; Meltzer and Massey, 2011; Yadav et al., 2011).

It has been suggested that to some extent a higher 5-HT2AR binding affinity, but a lower
D2R binding affinity, was the differentiation of SGAs from FGAs (Meltzer and Massey,
2011). It has also been reported that the blockade of 5-HT2AR, by olanzapine for
example, causes changes in dopaminergic output in the PFC (increase) and NAc
(decrease) throughout the nigrostriatal or mesolimbic dopaminergic pathways (Kuroki
et al., 2008). It should be noted that Richtand and colleagues reported that there was no
relation between the 5-HT2AR/D2R ratio and efficacy of SGAs (Richtand et al., 2007).
Some SGAs, such as amisulpride, have weaker 5-HT2AR affinity (Leucht et al., 2009).

B. The role of 5-HT2CR in therapeutic efficacy of SGAs
The 5-HT2CRs are located throughout the CNS, including the VTA and NAc (Pazos et
al., 1985), and are widely considered to be another of the serotonergic receptors
involved in the pathology of schizophrenia and response to SGAs (Dwyer et al., 2005;
Reynolds et al., 2005; Sodhi et al., 2005; Meltzer and Massey, 2011). Similar to the 5HT2AR antagonists, treatment by SGAs including olanzapine reduced the 5-HT2CR
binding level in the PFC, Cg and NAc (Tarazi et al., 2002; Huang et al., 2006b).

The 5-HT2CR plays an important role in regulating dopamine release (Meltzer and
Huang, 2008). For example, the firing rate of dopamine neurons in the VTA is inhibited
by 5-HT2CR agonists, but stimulated by 5-HT2CR antagonists (Meltzer and Huang,
2008). In addition, it was considered that 5-HT2CR inhibited dopamine release in the
PFC and NAc, which was consistent with microanalysis studies, in which the 5-HT2CR
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antagonist increased extracellular dopamine concentrations in the NAc and PFC (Millan
et al., 1998; Di Matteo et al., 2001; De Deurwaerdere et al., 2004). Furthermore, there
was evidence that a combined 5-HT2AR and 5-HT2CR blockade is more efficient than a
5-HT2AR blockade by itself to increase dopamine release in the NAc and PFC; the
combined blockade can interact reciprocally to modulate the activity of the mesolimbic
and the mesocortical dopaminergic pathways, and resulted in an improvement in
cognitive deficits (Meltzer et al., 2003). In addition, SGAs such as olanzapine,
clozapine, risperidone and ziprasidone showed potent inverse agonistic affinity at 5HT2CR in both humans and rats (Herrick-Davis et al., 2000). The 5-HT2CR agonist,
WAY-163909, is present in antipsychotic action in a variety of preclinical models
(Marquis et al., 2007). In addition, an association between the gene coding for 5-HT2CR
and olanzapine-induced weight gain (Sicard et al., 2010).

C. The role of 5-HTT in therapeutic efficacy of SGAs
The serotonin transporter (5-HTT) plays a key role in serotonergic neurotransmission
that terminates the action of serotonin and recycles it in a sodium-dependent manner via
transportation from the synaptic spaces into presynaptic neurons (Zhang and Malhotra,
2011). The 5-HTT gene (SLC6A4-solute carrier family 6, member 4) is associated with
various normal and pathological human behaviours including various psychiatric
disorders such as schizophrenia (Serretti et al., 2006; Dolzan et al., 2008). A number of
studies identified an association between 5-HTT gene polymorphism and the
symptomatology of schizophrenia, although there were some conflicting results (Fan
and Sklar, 2005; Dolzan et al., 2008; Zaboli et al., 2008). For example, using a
haplotype analysis, 5-HTT variants (5-HTTLPR, STin 2, rs104701, and rs1042173)
were reported to have a significant association with schizophrenia (Zaboli et al., 2008).
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Furthermore, the variations of 5-HTT gene polymorphisms and presence of 5-HTTLPR
L allele were relevant to the treatment response to SGAs including olanzapine (Serretti
et al., 2006; Bozina et al., 2007; Zhang and Malhotra, 2011). In particular, it has been
reported that, the short allele of 5-HTTLPR is linked with poor response to olanzapine,
clozapine and risperidone treatment, and affects the rate of 5-HT uptake (Serretti et al.,
2006; Zhang and Malhotra, 2011). On the other hand, 5-HTT, as the major route of
inactivation of 5-HT neurotransmission, affects the efficacy and tolerability of
antipsychotics; this may explain the ability of selective 5-HT reuptake inhibitors and
some antidepressants to inhibit 5-HT reuptake and cause EPS side-effects (Meltzer et al.,
2003). However, the exact role of 5-HTT in the SGA therapeutics of schizophrenia is
not clear.

2.2.2 Second generation antipsychotic drugs (SGAs) and weight gain/obesity sideeffects
2.2.2.1 Clinical evidence in SGA-induced weight gain
A series of clinical trials have shown that SGA treatment causes serious metabolic sideeffects (summarized by Deng, 2013, Allison et al., 2009). Clinical studies have
indicated that patients gain 4-5 kg of weight during the first 10 weeks’ of treatment with
some SGAs, such as olanzapine and clozapine, and may continue to gain weight
throughout the treatment period (Allison et al., 1999; Nasrallah, 2008). The NIH
(National Institutes of Health, USA) funded CATIE study (Clinical Antipsychotic Trials
of Intervention Effectiveness) reported the effects of 18 months’ of treatment with
SGAs including olanzapine, quetiapine, risperidone and ziprasidone on body weight
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gain side-effects; olanzapine treatment caused significant weight gain (≥7% from
baseline) (30% of schizophrenia patients, 0.9 kg/month), compared with quetiapine (16%
and 0.23 kg/month, respectively), risperidone (14% and 0.18 kg/month respectively)
and ziprasidone (7% and 0.14 kg/month respectively) (Lieberman et al., 2005). The
CAFE study (Comparison of Atypical Antipsychotics in First Episode Psychosis)
suggested that first-episode schizophrenia patients treated with olanzapine exhibited a
significant weight gain side-effects (59.8%), compared with risperidone (32.5%) and
quetiapine (29.2%) after 12 weeks’ of treatment (Patel et al., 2009). Furthermore, the
same investigators found that after 52 weeks’ of treatment, 80% of olanzapine-treated
patients (1.76 kg/month), compared to 57.6% of risperidone (1.28 kg/month) and 50%
of quetiapine-treated patients (1.29 kg/month), gained ≥ 7% body weight (Patel et al.,
2009). The European First Episode Schizophrenia Trial (EUFEST) showed a marked
weight gain in the first episode schizophrenia patients after one year treatment of
olanzapine (13.9 kg), quetiapine (10.5 kg), ziprasidone (4.8 kg), or haloperidol (7.3 kg)
(McQuade et al., 2004). A drug-naïve first episode psychosis study reported that the 7%
from base line weight gain was observed in 80% of olanzapine-treated patients, 58% of
risperidone and 50% of quetiapine patients (Zimmermann et al., 2003).

A number of clinical reports suggested that increasing appetite and food intake, as well
as delayed satiety signalling, are crucial behavioural changes associated with SGAinduced weight gain (Blouin et al., 2008; Sentissi et al., 2009; Deng, 2013). A 6 weeks
randomized double-blind study found that olanzapine-treated patients had higher rates
of food craving compared with clozapine (48.9% vs. 23.3%), as well as more frequent
and earlier occurring binge eating (16.7% and 1 week vs. 8.9% and 3 weeks) (Kluge et
al., 2007). It has also been reported that olanzapine treatment for one week significantly
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enhanced both anticipatory and consummatory reward responses to food rewards in the
brain’s reward circuitry including the SN, Cg and inferior frontal cortex, while inhibited
feeding behaviour and attenuated activation in brain regions such as the lateral orbital
frontal cortex (Mathews et al., 2012). Overweight and obesity are clinical conditions
that are associated with increased body fat and body mass index (BMI, weight in kg/the
square of height in meters, kg/m2) (Allison et al., 2009), especially increased visceral fat
in the abdomen which is associated with insulin resistance (Kenchaiah et al., 2004).
Therefore, the clinical trials indicated that chronic SGA treatment may lead to
substantial body weight gain/obesity side-effects; this may be due to increased energy
intake and reduced energy expenditure.

The development of SGA-induced weight gain/obesity side-effects can be divided into
three stages in humans (Figure 2.1A): firstly, the early acceleration stage in which
SGAs cause a rapid increase in body weight gain (about 3 months’ administration of
olanzapine and clozapine); secondly, a middle, steady increase stage involving a
steadier period of body weight gain lasting for up to 18 months; and lastly, weight
maintenance throughout the treatment period stage in which the heavier weight gain
level is maintained through the treatment period after 18 months (Zipursky et al., 2005;
Pai et al., 2012; Deng, 2013).

2.2.2.2 Animal models in SGA-induced weight gain
Because of the ethical issues related to human studies, appropriate animal models
mimicking the human scenario are important to examine the mechanisms of SGAinduced metabolic side-effects including weight gain (Choi et al., 2007; Tulipano et al.,
2007; Smith et al., 2008; Coccurello and Moles, 2010). In fact, multiple studies reported
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that olanzapine treatment has been modelled in rodents for investigating its metabolic
side-effects including body weight gain/obesity, hyperphagia, hypolocomotor activity,
hyperglycaemia and hyperinsulinaemia (Coccurello et al., 2006; Baptista et al., 2007;
Cooper et al., 2008; Cooper et al., 2010; Albaugh et al., 2011; Shobo et al., 2011; Van
Der Zwaal et al., 2014). In particular, animal models for olanzapine-induced weightgain/obesity have been successfully established in female rats in our laboratory (Huang
et al., 2006b; Han et al., 2008; Weston-Green et al., 2011; Deng et al., 2012), and other
labs (Coccurello et al., 2006; Chintoh et al., 2008; Cooper et al., 2008; Boyda et al.,
2012; Van Der Zwaal et al., 2014). The female rat models established in our laboratory
successfully mimicked the development of olanzapine-induced body weight
gain/obesity side-effects in humans (Huang et al., 2006a; Weston-Green et al., 2011).
They show three stages of development: in Stage 1, olanzapine-induced positive energy
balance is greatest and is characterised by an increased energy intake and rapid body
weight gain during the first 2 weeks; in Stage 2, an elevated body weight gain is
maintained during week 3-5, despite a lower increase in energy intake compared to
Stage 1; Stage 3 is characterised by the maintenance of an elevated body weight gain
and normal levels of energy intake (Figure 2.1B) (Huang et al., 2006b; Stefanidis et al.,
2008; Pai et al., 2012; Van Der Zwaal et al., 2014). Other studies have also investigated
animal rodent models for metabolic side-effects induced by other SGAs including
risperidone, quetiapine, ziprasidone and sulpiride (Baptista et al., 2002; Smith et al.,
2008; Savoy et al., 2010).
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(A)

(B)

Figure 2.1 (A): Body weight gain in schizophrenia patients treated with clozapine,
olanzapine and risperidone; (B): Body weight gain in a rodent model with olanzapine
treatment over 36 days compared to controls (Adapted from Pai et al., 2012; Huang et
al., 2006).

The studies in animal models showed that olanzapine-induced weight gain is caused at
least partly from increased food intake, reduced gross locomotor activity and
thermogenesis (Arjona et al., 2004; Weston-Green et al., 2011; Deng, 2013; Zhang et al.,
2014a). It has also been reported that female rats are more sensitive than male rats to
SGA-induced weight gain side-effects (Albaugh et al., 2006; Wu et al., 2007; WestonGreen et al., 2010), which is consistent with clinical observation that female
schizophrenia patients are more sensitive to

SGA-induced metabolic side-effects

compared with males (Bobes et al., 2003a; Hakko et al., 2006; Wu et al., 2007).
However, SGA-induced weight gain can only be modelled in male rats under certain
feeding conditions (Hartfield et al., 2003; Minet-Ringuet et al., 2006a; Shobo et al.,
2011), such as high carbohydrate/medium fat/low protein (54%/31%/14%) diets (MinetRinguet et al., 2006b; Shobo et al., 2011). Therefore, the female rat model for SGA-
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induced weight gain has been widely used for investigating the mechanisms of the sideeffects.

2.2.3 The neuropharmacological mechanisms of SGA-induced weight gain sideeffects
It has been recognised that increased energy intake (hyperphagia) and/or decreased
energy expenditure are the main reasons for body weight gain associated with SGAs
(Deng, 2013). A number of studies have shown that the robust potency of the
antagonistic binding affinity of SGAs for 5-HT2CR and histaminergic H1R is associated
with the weight gain side-effects of SGAs (Richelson and Souder, 2000; Rege, 2008;
Lencz and Malhotra, 2009; Deng et al., 2010; Reynolds and Kirk, 2010; He et al., 2013).
It was also suggested that increased appetite and food intake, as well as delayed satiety
signalling are the key factors related to SGA-induced weight gain/obesity side-effects
(Deng, 2013).

2.2.3.1 The function of the hypothalamus in body weight regulation
The hypothalamus is the main regulation centre for controlling energy balance and
feeding behaviour (Mercer et al., 2011). The distinct nuclei in the hypothalamus
including the arcuate nucleus (Arc), ventromedial hypothalamus (VMH) and lateral
hypothalamus (LH) share a reciprocal connection, and regulate body energy
homeostasis (Coppari et al., 2005; Sousa-Ferreira et al., 2014). More importantly, the
hypothalamic Arc is the vital modulation centre for energy balance, which projects to
other hypothalamic nuclei such as the VMH and LH (Hillebrand et al., 2002; MatsuiSakata et al., 2005; Dalvi et al., 2011).
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Furthermore, the Arc neurons produce orexigenic neuropeptides including neuropeptide
Y (NPY) and agouti-related protein (AgRP) that lead to upregulation of food intake, as
well as anorexigenic neuropeptides including proopiomelanocortin (POMC) and
cocaine-and amphetamine-regulated transcript (CART) that induce downregulation of
food intake (Mercer et al., 2011). It has been demonstrated that neurogenesis in the
hypothalamus participated in the response of hypothalamic neuronal circuits to
metabolic signals such as POMC and NPY (Kokoeva et al., 2005; Pierce and Xu, 2010;
Gouaze et al., 2013).

Since the Arc is an anatomical structure lacking a blood-brain barrier, peripheral signals
such as hormones and gastrointestinal peptides can reach the Arc (Schwartz, 2000;
Kohno and Yada, 2012). In fact, high densities of receptors for insulin, leptin and
ghrelin are identified in the Arc and other hypothalamic nuclei (Mercer et al., 2011).
Therefore, peripheral signals such as insulin and amylin (from the pancreas), ghrelin
(from the stomach), leptin and adiponectin (from adipose tissue) can be integrated to
contribute to the regulation of energy balance (Elmquist et al., 1998; Davidowa et al.,
2004; Davidowa and Plagemann, 2007; Mercer et al., 2011; Kohno and Yada, 2012).

2.2.3.2 The roles of hypothalamic neuropeptide and regulation of energy
homeostasis in SGA-induced weight gain
SGA-induced weight gain is associated with alterations to the neuroendocrine network
that controls appetite, food intake and satiety (Milano et al., 2013). As mentioned above,
the hypothalamic Arc plays a crucial role in appetite and energy homeostasis via
activation of 2 distinct neural populations, that are (1) anabolic/orexigenic neurons
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expressing NPY and AgRP, and (2) catabolic/anorexigenic neurons expressing POMC
and CART (Schwartz et al., 2000; Ak et al., 2013), which are involved in the regulation
of SGA-induced weight gain.

A. The roles of NPY and AgRP
As a 36 amino acid peptide, NPY has emerged as one of the most potent orexigenic
hypothalamic neuropeptides (Smitka et al., 2013; Zhang et al., 2014c), having been
isolated originally from a porcine brain, and is synthesized in both the central and
peripheral neurons (Tatemoto et al., 1983). In the CNS, NPY is mainly synthesized in
the hypothalamus, brainstem and anterior pituitary (Zhang et al., 2014c). Specifically,
the Arc NPY neurons project to adjacent hypothalamic regions including LH, the
paraventricular nucleus (PVN), the dorsomedial nucleus (DMN), and the perifornical
areas (PFO) (Morris, 1989). As the biomarker for obesity, NPY is a major mediator in
promoting energy storage (Zhang et al., 2014c), which regulates fat deposition and
metabolism via various G-protein-coupled NPY receptors (NPYRs) including NPY
receptor subtype 1, 2, and 5 (Larhammar et al., 1993). For example, the NPY receptor
sub-type 5 antagonist, Velneperit, has been identified in clinical tests as a potential
anti-obesity drug (George et al., 2014).

It has been reported that a single intracerebroventricular (ICV) injection of NPY
stimulated feeding in rats (Clark et al., 1984), sheep (Miner et al., 1989) and monkeys
(Larsen et al., 1999). Furthermore, injection of NPY into the PVN repeatedly led to
sustained hyperphagia, body weight gain and fat mass accumulation (Stanley and
Thomas, 1993), while decreased heat production in brown adipose tissue (BAT)
resulted in the anabolic effects of NPY via inhibition of the sympathetic nervous system
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(SNS) (Stanley et al., 1986; Egawa et al., 1990; Billington et al., 1991). In addition,
synthesis and secretion of Arc NPY resulted in response to energy deficiency and
greater metabolic need such as increased exercise, cold and pregnancy (Leibowitz and
Wortley, 2004; Mercer et al., 2011). Therefore, NPY promotes energy storage by
hyperphagia and decreased energy expenditure (Morton and Schwartz, 2001). Moreover,
the Arc NPY neurons play a role in integrating peripheral energy signals, such as blood
glucose concentration, ghrelin, leptin and insulin (Kohno and Yada, 2012). In particular,
food intake is stimulated by increasing NPY signalling, and inhibited by insulin and
leptin (Morton and Schwartz, 2001).

AgRP is synthesised exclusively in the Arc that projects to adjacent hypothalamic
regions such as the PVN, DMN and LH (Suzuki et al., 2012). The major function of
AgRP is to stimulate feeding by antagonising melanocortins at the MC 3R (melanocortin
3 receptor) and MC4R (melanocortin 4 receptor) in the hypothalamus (Broberger et al.,
1998; Haskell-Luevano et al., 1999; Nijenhuis et al., 2001; Cone, 2005). Polymorphism
of the AgRP gene is associated with inherited leanness in humans (Marks et al., 2004).
Similar to NPY, both leptin deficiency (ob/ob) and leptin receptor mutation (db/db)
resulted in overexpression of AgRP in the Arc of mice (Ollmann et al., 1997; Cone,
2005), which has also arisen from fasting in rats and mice (Shutter et al., 1997). AgRP
is sustained for up to a week after a single ICV injection, compared with the effects of
NPY which are sustained over hours (Hagan et al., 2000; Schwartz et al., 2000).
Selective ablation of NPY/AgRP-expressing nuclei in adult mice resulted in acute
reduction of feeding (Gropp et al., 2005).
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The effects of SGAs on expression of NPY and AgRP have been addressed in previous
studies. In particular, Fernø and colleagues demonstrated that short-term exposure to
olanzapine (6 days) resulted in upregulated NPY and AgRP expressions in the Arc of
both rats fed ad libitum and pair-fed rats (Fernø et al., 2011). Furthermore, the increased
hypothalamic NPY and AgRP expressions were also observed by the study using ICV
administration of olanzapine (Martins et al., 2010). A recent study in our group also
reported that the NPY level was upregulated in short (7 days) and mid-term (15 days)
olanzapine treatment in rats and in another 8 days of pair-fed experiment (Zhang et al.,
2014a) (summarised in Figure 2.3). The same authors further revealed elevated NPY
and AgRP expressions after an acute ICV injection of olanzapine, which was associated
with increased food intake (Zhang et al., 2014a). Another study from our group also
reported that olanzapine upregulated NPY mRNA expression in the hypothalamic Arc
(Weston-Green et al., 2012). NPY upregulation has also been reported in other SGAs:
clozapine enhanced hypothalamic NPY expression in rats (Kirk et al., 2006), while
quetiapine increased the NPY level in cerebrospinal fluid from schizophrenia patients
(Nikisch et al., 2012); which were associated with SGA-induced weight gain. The
association between AgRP and fat mass as well as appetite have been examined and
were found to be disrupted in olanzapine-treated patients, but not in patients treated
with ziprasidone (Ehrlich et al., 2012). However, some studies reported that
hypothalamic NPY expression following SGAs exposure either decreased or did not
change (Huang et al., 2006a; Davoodi et al., 2009; Guesdon et al., 2010; Secher et al.,
2010). Ak and colleagues also reported that the plasma NPY level was attenuated in
first attack psychotic male patients treated with olanzapine (Ak et al., 2013). These
conflicting observations may be attributed to methodological differences including
treatment duration, drug dosage and delivery methods (oral, intraperitoneal, or ICV
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injection) (Huang et al., 2006a; Kirk et al., 2006; Davoodi et al., 2009; Guesdon et al.,
2010; Martins et al., 2010; Fernø et al., 2011). Other studies have observed the various
effects of SGAs on NPY expression in different brain regions (Obuchowicz and
Turchan, 1999; Obuchowicz et al., 2004; Huang et al., 2006a; Weston-Green et al.,
2012).

On the other hand, Ruano and colleagues reported that a polymorphism (rs1468271) in
the NPY gene had no association with body weight gain in patients treated with
olanzapine and risperidone (Ruano et al., 2007). A recent study by Tiwari and
colleagues suggested a significant association between the SNPs rs16147, rs5573, and
rs5574 in NPY and weight gain in clozapine and olanzapine-treated patients (Tiwari et
al., 2013). The same authors also revealed an association of rs6837793, near NPY5R,
with the weight gain profile in patients treated with risperidone, which supported the
role of the NPY system in SGA-induced weight gain.

B. The roles of POMC and CART
POMC is synthesized from the 285-amino-acid-long polypeptide precursor, and
produces peptide hormones including β-endorphins and melanocortin (Morton and
Schwartz, 2001; Cone, 2005). There are several subtypes of the melanocortin peptides,
such as adrenocorticotrophin (ACTH) and alpha-melanocyte-stimulating hormone (αMSH), which act at G-protein-coupled melanocortin receptors such as the MC1-5
receptors (Morton and Schwartz, 2001; Cone, 2005; Millington, 2006). In the brain,
POMC is mainly expressed in the Arc (Morton and Schwartz, 2001; Millington, 2006).
The POMC neurons project to the periventricular, paraventricular and perifornical
regions of the hypothalamus (Jobst et al., 2004; Cone, 2005). It is also reported that
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POMC mRNA expression is increased by leptin and co-localized with leptin receptors
(Cheung et al., 1997; Schwartz et al., 1997; Thornton et al., 1997; Mizuno et al., 1998b;
Fry et al., 2007).

Certain POMC gene mutations may contribute to obesity in healthy human populations
(Krude et al., 1998; Baker et al., 2005; Ternouth et al., 2011), while mouse knockout for
POMC also shows the obese phenotype (Yaswen et al., 1999; Millington, 2006). POMC
mRNA expression is reduced by food restriction, while increased by overfed rats
(Mizuno et al., 1998a; Hagan et al., 1999). Importantly, the activation of POMC
neurons is regulated by the binding of 5-HT to 5-HT2R (Reynolds and Kirk, 2010; Ak et
al., 2013). Additionally,

POMC expression in the Arc is also regulated by the

dopaminergic system via D2R (Tiligada and Wilson, 1989).

CART is a peptide (first isolated from the ovine hypothalamus), and is widely
distributed throughout the central and peripheral nervous systems (Vicentic and Jones,
2007; Zhang et al., 2012). CART protein is encoded by the CARTPT gene, which
functions in feeding, reward, stress and pain transmissions (Douglass and Daoud, 1996;
Kristensen et al., 1998). Similar to POMC, CART also downregulates food intake and
body weight (Nakhate et al., 2011). A previous study has revealed that CART has an
effect on neuronal activities, including the hypothalamic VMH and PVN, which are
involved in the neuroplasticity of hypothalamic feeding circuits (Davidowa et al., 2005).
Furthermore, CART interacts with other important mediators such as the cannabinoid
CB1 receptor, insulin and leptin, involved in the regulation of feeding (Cota et al., 2006;
Vicentic and Jones, 2007). On the other hand, ICV administration of CART was
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accompanied by a decrease in plasma insulin and leptin levels and an increase in lipid
oxidation, which limits fat storage (Rohner-Jeanrenaud et al., 2002).

It was shown that olanzapine treatment resulted in attenuation of POMC but not CART
expressions in the hypothalamus of rats (Fernø et al., 2011; Sezlev et al., 2013; Zhang et
al., 2014a). For example, a recent study in our group reported that olanzapine reduced
hypothalamic POMC levels after short (7 days) and medium (15 days) term olanzapine
treatment (Zhang et al., 2014a). Another study from our group also revealed that
olanzapine significantly attenuated POMC mRNA expression in the Arc of rats treated
with olanzapine (Weston-Green et al., 2012). Rats treated with olanzapine (6 days)
showed a reduced hypothalamic POMC expression, but no change in CART (Fernø et
al., 2011). Ak and colleagues also reported that the plasma POMC level was elevated in
first attack psychotic male patients treated with olanzapine, but no changes in plasma
CART level were observed (Ak et al., 2013). It should be noted that olanzapine
suppresses POMC expression by blocking 5-HT2CR, and indirectly blocking 5-HT1B
receptor (5-HT1BR), while that suppression is abolished by GABA (gammaaminobutyric acid) neurons (Donovan and Tecott, 2013) (summarised in Figure 2.3).
However, it should also be noted that there are some conflicting reports. Two studies
reported no alteration of POMC expression when treated with olanzapine, one in rats
(Davoodi et al., 2009) and the other in patients (Chowdhury et al., 2014). A recent
genetic study reported that neither the POMC single nucleotide polymorphisms
(rs6713532, rs1047521, rs3754860) nor the CART (SNPs) (rs10515115, rs3763153,
rs3857384, rs11575893, rs16871471) gene variants was associated with weight gain in
chronic schizophrenia patients treated with SGAs (Chowdhury et al., 2014). In addition,
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a genetic polymorphism study suggested that MC4R is relevant to SGA-induced weight
gain and related metabolic disorders (Malhotra et al., 2012).

2.2.3.3 The role of serotonin neurotransmission associated with SGA-induced
weight gain
Serotonin neurotransmation plays a key role in regulating food intake (Meguid et al.,
2000; De Vry et al., 2003). It has been reported that 5-HT2CR gene knocked-out mice
have been proven to develop hyperphagia, which further led to obesity and
hyperinsulinemia (Tecott et al., 1995; Meier and Gressner, 2004). It was also reported
that food intake was reduced by 5-HT2CR agonist, but increased by a 5-HT2CR
antagonists (Kitchener and Dourish, 1994; Clifton et al., 2000; Schreiber and De Vry,
2002; Hayashi et al., 2005).

Over the past 2 decades, SGA-induced weight gain has been partially attributed to the 5HT2CR antagonist properties of SGAs (Reynolds and Kirk, 2010; Meltzer, 2013).
Furthermore, some SGAs, including olanzapine and clozapine, are also inverse agonists
on 5-HT2CR, rather than full antagonists (Rauser et al., 2001; Kirk et al., 2009), which
also plays a crucial role in SGA-induced weight gain (Kirk et al., 2009). Additionally, it
has been reported that co-treatment of haloperidol (a D2R antagonist) with SB243213 (a
5-HT2CR antagonist) mimicked olanzapine induced body weight gain in rats (Berg et al.,
2006; Kirk et al., 2009).

Furthermore, 5-HT has been found to influence appetite by activating anorexigenic
POMC neurons and melanocortin-4 receptors (Lam et al., 2010). In particular,
serotonergic neurons project to the hypothalamic POMC neurons where they co-express
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5-HT2CR (Donovan and Tecott, 2013). Therefore, as a potent 5-HT2CR antagonist or
inverse agonist, olanzapine may decrease expression of POMC by blocking the 5HT2CR that increases appetite (Xu et al., 2008; Lam et al., 2010) (summarised in Figure
2.3).

2.2.3.4 The role of histamine neurotransmission in SGA-induced weight gain
Histamine neurons originate from the tuberomammilary nucleus (TMN) of the posterior
hypothalamus (which receives very dense of orexin innervations originating from the
LH) and project to all brain regions including the hypothalamus itself (Schwartz et al.,
2000; Brown et al., 2001; Haas et al., 2008; Masaki and Yoshimatsu, 2010). Since
histamine cannot cross the blood-brain barrier, it is synthesised in situ in the brain from
the precursor amino acid, L-histidine and catalysed by the rate-limiting enzyme histidine
decarboxylase (HDC) (Jorgensen et al., 2006).

Histamine exerts its actions via the specific histaminergic receptors, which have been
classified into the H1, H2, H3 and H4 subtypes (Brown et al., 2001; Masaki and
Yoshimatsu, 2006). All of them are G-protein-coupled receptors and widely expressed
throughout the body. In the CNS, the H1 receptors (H1R) are mainly postsynaptically
located and are found especially in the hypothalamus, cerebral cortex and limbic system
(Lintunen et al., 1998; Brown et al., 2001), where they are well documented as involved
in the regulation of body weight and food intake. H2 receptors are also mainly
postsynaptically located and are expressed in the hippocampus, amygdala and basal
ganglia (Brown et al., 2001). H3 receptors (H3R) are exclusively presynaptically located
and found in the NAc, striatum, basal ganglia, and hypothalamus (Arrang et al., 1983;
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Brown et al., 2001). H4 receptors are expressed in the hypothalamus and spinal cord
(Strakhova et al., 2009).

Histamine plays a crucial role in the regulation of a wide range of behavioural and
physiological functions in humans and animals, such as appetite, drinking, sleep,
wakefulness, locomotor activity, learning and memory (Brown et al., 2001; Passani et
al., 2011). In particular, the neurotransmitter histamine has been implicated in the
regulation of energy homeostasis (Park et al., 1999; Deng et al., 2010). In other words,
elevated hypothalamic histamine signalling contributed to decreased food intake and
body weight gain in animals including rats (Clineschmidt and Lotti, 1973; Itowi et al.,
1988; Lecklin et al., 1998; Masaki and Yoshimatsu, 2010), while reduction in histamine
levels was associated with increased body weight gain and food intake (Brown et al.,
2001; Passani et al., 2011). Histamine knockout mice exhibited predominantly obesity
with increased visceral adiposity, hyperleptinemia and decreased glucose tolerance
(Fulop et al., 2003; Jorgensen et al., 2006). It has also been reported that SGAs such as
olanzapine can directly modulate histaminergic neurotransmission in the hypothalamus,
which correlated with the regulation of feeding behaviour in rats (Davoodi et al., 2008).

A. H1R and SGA-induced weight gain
The histaminergic H1Rs are highly expressed in the hypothalamic Arc, VMH and PVN
(Masaki et al., 2004), which are involved in the regulation of food intake and energy
expenditure (Yoshimatsu et al., 2002; Poole et al., 2008; Masaki and Yoshimatsu, 2010).
It has been reported that H1R antagonists play a crucial role in increasing appetite and
obesity development (Tecott et al., 1995; Deng et al., 2010), which were also observed
in H1R knockout (KO) mice (Masaki et al., 2004). Moreover, deprivation of food
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predominantly led to activation of H1R expression in the hypothalamic Arc (Umehara et
al., 2010). It was also demonstrated that ICV injection of the H1R agonist, 2-(3trifluoromethylpehenyl)histamine (FMPH) inhibited food intake (He et al., 2014).

H1R antagonist properties have been identified as playing a significant role in the
development of SGA-induced body weight gain/obesity side-effects (approximately
Clozapine = Olanzapine > Quetiapine > Risperidone > Haloperidol > Ziprasidone =
Aripiprazole) (Kroeze et al., 2003; Matsui-Sakata et al., 2005; Correll, 2008; Coccurello
and Moles, 2010) (Table 2.1). In particular, H1R blockade is recognised as a
predominant target for SGA-induced weight gain compared with other receptors (Dwyer
et al., 2005; Stahl et al., 2009; Meltzer, 2013). A previous study in our laboratory
showed that short (1 week) and long (12 weeks) term treatments with olanzapine (0.5
mg/kg, t.i.d.) significantly changed H1R mRNA expression in the hypothalamic Arc and
VMH, which was significantly correlated with food intake, body weight gain, feeding
efficiency and fat pad mass (Han et al., 2008). Similarly, clinical studies demonstrated
patients treated with antipsychotics showed a significant correlation between the genetic
variants of H1R (rs346074 – rs346070), BMI and obesity (Vehof et al., 2011).

Since histamine cannot pass the blood-brain barrier, direct peripheral H1R antagonism
by SGA treatment may also contribute to the obesity side-effects (He et al., 2013; He et
al., 2014). The H1R antagonistic affinity of SGAs is significantly correlated not only
with increased body weight and adiposity, but also with insulin-resistance in
schizophrenia patients (Erhart et al., 1998; Wirshing et al., 1999). Other antihistamine
drugs such as loratadine and cyproheptadine have been associated with increased body
weight and hyperphagia (Silverstone and Schuyler, 1975; Saleh et al., 1979; Chervinsky
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et al., 1994). Furthermore, the H1R antagonistic affinity of SGAs contributes to fat
accumulation via downregulation of lipolysis, while upregulating lipogenesis in white
adipose tissue (Lundius et al., 2010; Teff and Kim, 2011).

B. H3R and SGA-induced weight gain
In addition to H1R, the histaminergic H3R is another significant target for regulating
food intake and is highly expressed in the TMN of the hypothalamus (Pillot et al., 2002;
Deng et al., 2010). Furthermore, H3 heteroreceptors are also located on nonhistaminergic neurons, regulating release of neurotransmitters such as acetylcholine,
serotonin and dopamine, which may also be involved in food intake regulation
(Threlfell et al., 2004; Passani et al., 2011).

SGAs maintain a very weak antagonistic potency at histaminergic H3Rs in the brain
(Schlicker and Marr, 1996) (Table 2.1). As a result, H3R may play an indirect role in
regulating the weight gain/obesity side-effects induced by SGAs. For example, it is
possible that olanzapine can block postsynaptic H1Rs, which may then lead to
accumulation of histamine in the synaptic cleft (Deng et al., 2010) (summarised in
Figure 2.3). Since the release and synthesis of histamine are regulated by presynaptic H3
autoreceptors (Gomez-Ramirez et al., 2002), the accumulated histamine then activates
the pre-synaptic H3R slowing the synthesis and secretion of histamine and heightening
feeding behaviour (Takahashi et al., 2002; Chiba et al., 2009; Deng et al., 2010). On the
other hand, it was found that intraperitoneal injection of risperidone immediately
increased hypothalamic histamine release, that was regulated by H3R (Murotani et al.,
2011).

Jiamei Lian

34

2.2.4 The role of hypothalamic H1R-AMPK signalling in SGA-induced weight gain
Hypothalamic AMP-activated protein kinase (AMPK) is highly expressed in the Arc,
PVN, VMH and LH of the hypothalamus (Minokoshi et al., 2004; Kim et al., 2007;
Meltzer, 2007; Kohno et al., 2011). It has been suggested that AMPK activity could be
inhibited by histamine in hypothalamic tissue slices, while it is activated by H1R
antagonist, triprolidine in both hypothalamic tissue slices and the hypothalamus of
knock-out mice (Kim et al., 2007). In addition, it is important to note that hyperphagia
in diet-induced obese animals is attributed to the effect of hypothalamic AMPK
signalling (Martin et al., 2006). Kahn and colleagues showed that AMPK activity in the
hypothalamic Arc and PVN was inhibited by anorexigenic leptin and augmented by
orexigenic AgRP (Kahn et al., 2005). Hypothalamic AMPK is also involved in feeding
regulation and food intake by regulating the AMPK-ACC-Malonyl-CoA-CPT1 axis
(ACC: acetyl-CoA carboxylase; CPT1: carnitine palmitoyltransferase 1) (Kola, 2008;
Lage et al., 2008; Ronnett et al., 2009). A study using the CT1-1 cell line reported that
the protein level of phosphor-AMPK (pAMPK) is activated by the H1R antagonist,
chlorpheniramine, while it is blocked by histamine (Kang et al., 2012).

It was found that olanzapine and clozapine activated hypothalamic AMPK by blocking
H1Rs to increase food intake and body weight gain (Kim et al., 2007; Meltzer, 2007;
Sejima et al., 2011; Skrede et al., 2014) (Figure 2.2). In hypothalamic tissue slices, the
level of pAMPK can be enhanced markedly by olanzapine, which indicates that the
weight gain/obesity side-effects associated with olanzapine is mediated by activation of
hypothalamic AMPK linked to blockade of the histaminergic H1R (Kim et al., 2007;
Meltzer, 2007). Our previous study found a time-dependent change in hypothalamic
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AMPK signalling in SGA-induced obesity: the hypothalamic pAMPK level was
increased after an 8-day administration of olanzapine (1 mg/kg, t.i.d.), followed a return
to normal levels after 15 days’ of treatment, and significantly reduced after 36 days of
treatment (He et al., 2014). Additionally, administration of olanzapine by acute ICV
infusion increased hypothalamic pAMPK expression (Martins et al., 2010). Therefore,
besides H1R itself, its downstream AMPK signals are also valuable targets for treating
SGA-induced weight gain/obesity side-effects (Deng et al., 2010; He et al., 2013)
(summarised in Figure 2.3).

Histamine
neuron

Histamine
H3R

Arc/VMH
H1R neuron AMPK

pAMPK

: Olanzapine
(H1R blockade)

H1R: H1 receptor
H3R: H3 receptor
: Arcuate nucleus
Arc:
VMH: Ventromedial Nucleus
: activating

Figure 2.2 The proposed mechanisms of olanzapine-induced weight gain through
histaminergic H1 receptors. Olanzapine can block hypothalamic H1 receptors and
activate AMPK, which increases food intake and weight gain.
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2.2.5 The role of brown adipose tissue in energy homeostasis associated with SGAinduced weight gain
Brown adipose tissue (BAT) functions by transferring energy from food into heat, burns
lipids for thermogenesis and energy expenditure, and is also abundantly innervated by
the sympathetic nervous system (SNS) (Oh et al., 2012). As another primary energy
storage reservoir, BAT has an opposite role to white adipose tissue (WAT), which
dissipates chemical energy producing heat generation via non-shivering thermogenesis,
rather than storing and releasing energy in the form of triglycerides (Uldry et al., 2006;
Stefanidis et al., 2008; Oh et al., 2012; Zhang et al., 2014c).

It has been indicated that treatment with obesogenic SGAs is associated with decreased
energy expenditure both in patient and animal models (Blessing et al., 2006; Stefanidis
et al., 2008; Skouroliakou et al., 2009; Cuerda et al., 2011; Zhang et al., 2014b)
(summarised in Figure 2.3). In humans, BAT is distributed mainly in the interscapular
of early neonates and adults and is predominately involved in energy balance such as
regulation of body weight gain (Tam et al., 2012). In rodents, it was revealed that SGAs
including clozapine, quetiapine and ziprasidone were prone to induce weight gain by
inhibition of thermogenesis in BAT (Ota et al., 2002; Blessing et al., 2006; Oh et al.,
2012). In addition, a study of psychotropic-induced obesity showed that lithium, a
bipolar disorder therapy, downregulated the differentiation of mouse BAT (Rodriguez
de la Concepcion et al., 2005).
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2.2.5.1 Uncoupling peptide 1 (UCP1) in SGA-induced weight gain
Thermogenesis of BAT is a response to cold exposure or diet, and occurs through the
activation of uncoupling peptide 1 (UCP1), which is a protein located in an innermitochondrial membrane that uncouples the mitochondrial proton gradient leading to
oxygen consumption (Klingenberg and Huang, 1999; Rosen and Spiegelman, 2006). It
has been reported that the noradrenaline released from the SNS nerve endings in BAT
activates β-adrenergic receptors, BAT cell proliferation and mitochondriogenesis, and
increased expression of UCP1 (Himms-Hagen, 1990). As discussed above,
hypothalamic AMPK co-operating with other neurotransmitters/neuropeptides, plays
significant roles in regulating energy homeostasis such as hyperphagia and obesity
(Lage et al., 2008; Lim et al., 2010). In addition, hypothalamic H1R-pAMPK can
regulate UCP1 and BAT thermogenesis (Yasuda et al., 2004; Skrede et al., 2014).

It was recently demonstrated that clozapine significantly downregulated the expression
of UCP1 in BAT, while quetiapine suppressed the UCP1 but less strongly compared with
clozapine, and ziprasidone did not affect UCP1 (an SGA with weight gain side-effects)
(Oh et al., 2012). A more recent study in our lab also found long term (35 days)
treatment of olanzapine reduced UCP1 protein expression in the BAT of rats, which is
associated with decreased BAT thermogenesis (Zhang et al., 2014b). Previous studies
revealed that olanzapine treatment significantly reduced UCP1 protein expression in
BAT (Stefanidis et al., 2008; Hu et al., 2014). However, a weaker correlation between
mRNA and protein levels of UCP1 has been reported, having found that UCP1 mRNA
was unaltered after olanzapine treatment (Stefanidis et al., 2008; Nedergaard and
Cannon, 2013); this suggested that olanzapine increases mainly UCP1 protein
production, not UCP1 mRNA expression (summarised in Figure 2.3).
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2.2.5.2 PGC-1 in SGA-induced weight gain
The peroxisome proliferator-activated receptor γ (pPPARγ)-coactivator 1ɑ (PGC-1ɑ) is
expressed in the heart, kidneys, BAT, and brain; it was originally described as a coldinducible coactivator controlling thermogenesis in the BAT and skeletal muscle by
regulating the metabolism from mitochondrial biogenesis and respiration to hepatic
gluconeogenesis (Houten and Auwerx, 2004). Besides PGC-1ɑ, PGC-1β is also a
member of the transcriptional coactivators playing a critical role in BAT thermogenesis
(Houten and Auwerx, 2004; Uldry et al., 2006).

PGC-1ɑ plays a pivotal role in brown adipose cells including mitochondrial biogenesis
and UCP1 activity in relation to thermogenesis of BAT (Puigserver et al., 1996;
Puigserver et al., 1998). Furthermore, ectopic expression of PGC-1ɑ is sufficient to
promote several aspects of differentiation toward to the brown fat lineage, including the
induction of UCP1 gene expression (Uldry et al., 2006). PGC-1ɑ is also rapidly and
strongly induced by cold exposure, which is also confirmed by a mice study in which
PGC-1ɑ deficiency led to cold sensitivity and low UCP1 expression (Lin et al., 2004). In
addition, PGC-1ɑ deficiency observed in the brain, hepatocytes and muscle contributed
to deficient BAT function in PGC-1ɑ-/- mice (Houten and Auwerx, 2004; Lin et al.,
2004). The previous study suggested that deficiency of either PGC-1ɑ or PGC-1β
caused a significant decline in mitochondrial gene expression including UCP1 during
differentiation (Uldry et al., 2006). It is worth noting that, besides BAT thermogenesis
and UCP1, PGC-1a expression is also modulated by hypothalamic AMPK signalling
(Lopez et al., 2010; Morrison et al., 2014).
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PGC-1ɑ is related to SGA-induced weight gain side-effects (Oh et al., 2012; Hu et al.,
2014; Zhang et al., 2014b). For example, Zhang and colleagues reported a
downregulated PGC-1ɑ expression in the BAT of rats, treated by long-term
administration of olanzapine, which was associated with reduced BAT temperature
(Zhang et al., 2014b). It has been reported that clozapine significantly reduced the
expression of mouse brown adipogenesis markers including PGC-1ɑ (Oh et al., 2012)
(summarised in Figure 2.3). In addition, a recent rat study also suggested that
olanzapine significantly reduced PGC-1ɑ expression in skeletal muscle, while gene
expression of PGC-1ɑ was increased after co-treatment with olanzapine and metformin,
and co-treatment with berberine (a herbal alkaloid), compared with olanzapine
treatment alone

(Hu et al., 2014). To date, it is not clear whether PGC-1β also

contributes to SGA-induced weight gain.

As discussed above, SGAs may induce body weight gain side-effects by elevating
hypothalamic H1R-AMPK pathway and NPY, AgRP expressions, while attenuating
POMC levels. Furthermore, BAT thermogenesis biomarkers UCP1 and PGC-1a, and
locomotor activity, are also involved in regulation of SGA-induced weight gain (Figure
2.3).

Jiamei Lian

40

Jiamei Lian
Jiamei
Lian

41

Figure 2.3 A proposed mechanism underlying SGA-induced body weight gain/obesity side-effects through regulation of energy intake and
expenditure. On one hand, SGAs block the histamine H1 receptors. The H1R blockade by SGAs may cause a compensatory upregulation of
H1R density in the hypothalamus, and enhance hypothalamic AMPK, NPY and AgRP expressions. SGAs may downregulate POMC levels
through acting on 5-HT2CR. On the other hand, SGAs may reduce thermogenesis by attenuating UCP1 and PGC-1α expressions in BAT,
which could also be modulated by hypothalamic H1R-AMPK signalling. In addition, decreased energy expenditure could also be due to
reduced locomotor activity caused by SGA treatment.

Abbreviations: 5-HT2CR, serotonin 5-HT2C receptor; AgRP, agouti-related peptide; AMPK, active protein kinase; BAT, brown adipose
tissue; H1R, histamine H1 receptor; NPY, neuropeptide Y; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha;
POMC, pro-opiomelanocortin; UCP1, uncoupling protein 1.
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2.2.6 Interventions/treatment for ameliorating SGA-induced weight gain sideeffects
2.2.6.1 Current status of pharmacologic interventions for controlling SGA-induced
weight gain
Regarding pharmacological interventions, a number of drugs have been trialled with
some success in partially ameliorating SGA-induced weight gain side-effects. A metaanalysis study examined 25 pharmacologic weight loss intervention trials (n=1221) and
revealed that amantadine, metformin, reboxetine, sibutramine and topiramate were
effective in reducing SGA-induced weight gain (Baptista et al., 2008). Another metaanalysis of 32 placebo-controlled pharmacologic intervention trials involving 1482
subjects suggested that metformin had the most promising effect on weight loss,
followed by fenfluramine, sibutramine, topiramate, and reboxetine (Maayan et al.,
2010). Other clinical trials also showed a similar effect of metformin in attenuating
antipsychotic-induced weight gain (Morrison et al., 2002; Baptista et al., 2008; Shin et
al., 2009; Weaver et al., 2010; Jarskog et al., 2013). However, another study showed
that co-treatment of metformin with risperidone had no significant effect in reducing
weight gain (Arman et al., 2008). A recent study reported that both metformin and
berberine treatment did not affect food intake, but significantly prevented olanzapineinduced brown fat loss (Hu et al., 2014). The same author further found that UCP1
expression was significantly increased after co-treatment of metformin and olanzapine,
compared with olanzapine only treatment (Hu et al., 2014). In addition, metformin and
rosiglitazone can also reduce glucose intolerance and insulin resistance in patients
treated with SGAs (Baptista et al., 2009; Ehret et al., 2010). The potential of zoisamide,
sibutramine and topiramate have also been addressed as adjuvant treatments for weight
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loss of schizophrenic patients treated with SGAs (Das et al., 2012; Fiedorowicz et al.,
2012; Ghanizadeh et al., 2013).

It is worth noting that some pharmacological interventions can cause additional health
risks (Maayan et al., 2010). For example, metformin led to lactic acidosis, especially in
the elderly, nausea, vomiting and diarrhoea, while topiramate was associated with
cognitive blunting (Maayan et al., 2010; Narula et al., 2010; Loke et al., 2011).
However, to date, these pharmacological intervention studies were not based on the
mechanism of SGA-induced weight gain, particularly considering H1R and 5-HT2CR as
key contributors for SGA-induced weight gain. Therefore, it is important to investigate
the potential for targeting H1R and 5-HT2CR to control SGA-induced weight gain,
which has been addressed partially in the current study (by targeting H1R).

2.2.6.2 The H1R agonist as a target for controlling SGA-induced weight gain
As reviewed above, the antagonistic property of histaminergic H1R is the major
contributor to SGA-induced weight gain side-effects; therefore, there is great potential
for controlling the weight gain by targeting H1R. The question is therefore whether an
H1R agonist could be used to prevent and treat olanzapine-induced obesity. One
candidate is FMPH, a selective H1R agonist, which has been shown to have some
potential to reverse olanzapine-induced hyperphagia after ICV injection (He et al.,
2014). Unfortunately, it is unable to cross the blood-brain barrier (Malmberg-Aiello et
al., 1998), and there is no other highly selective and orally deliverable H 1R agonist on
the market.
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Another significant candidate is betahistine (C8H12N2), which is readily available in
clinics with a highly safety profile (1:100000 reported adverse drug reactions), and has
been used to treat more than 130 million patients suffering vestibular disorders such as
vertigo and dizziness since the 1970s (Jeck-Thole and Wagner, 2006; Tighilet et al.,
2007). It has been used as an anti-obesity drug in clinical trials. A randomised, doubleblind placebo-controlled trial reported that 32 mg/day treatment of betahistine to 20
obese subjects for 28 days resulted in 1.1% weight loss, compared to 0.6% weight gain
in the placebo group (Barak, 2008). Barak and colleagues also reported that 12 weeks’
treatment of betahistine (16-48 mg/kg) in 281 adults led to significant weight loss in the
subgroup of non-Hispanic women ≤50 years old with 48 mg/day betahistine treatment
(Barak, 2008).

Betahistine acts as a modulator of the histaminergic system and has both H1R-agonistic
and H3R-antagonistic properties in the brain (Yoshida et al., 2000; Fossati et al., 2001).
Based on our previous study (Deng et al., 2012), it is proposed that, under normal
conditions, histamine may activate H1R on the hypothalamic neurons, leading to a
decrease in food intake. However, olanzapine blocks histaminergic H1R on the
hypothalamic neurons causing an increase in food intake (Figure 2.4A). As an H1R
agonist, betahistine can directly activate H1R and may compete with olanzapine for
binding to H1R, therefore reducing the H1R antagonist property of olanzapine. On the
other hand, betahistine, as an H3R antagonist, increases histamine release by blocking
presynaptic H3R, which may augment its direct agonistic effects on H1R (Figure 2.4B)
(Deng et al., 2012).
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Figure 2.4 (A): The possible mechanism of Histamine H1 and H3 receptor regulation of
food intake (Abbreviation: DVC-Dorsal vagal complex); (B): Olanzapine-induced body
weight gain could be significantly reduced by co-administration with betahistine
through activating postsynaptic H1R and blocking presynaptic H3R (From Deng et al.,
2012, reprinted with permission of SAGE).

Interestingly, the combined histaminergic H1R/H3R action of betahistine has been
proven to be efficient in increasing satiety and reducing the desire to eat fatty foods in
rats (Szelag et al., 2001). Furthermore, a small clinical trial (in three first-episode
schizophrenia patients) found that betahistine was able to reduce olanzapine-induced
weight gain following 6 weeks’ of co-treatment with olanzapine and betahistine (O+B)
(Poyurovsky et al., 2005). The same author also reported that co-administration with
olanzapine, betahistine and reboxetine (a selective norepinephrine reuptake inhibitor) in
Jiamei Lian

46

first episode schizophrenia patients resulted in significantly attenuated weight gain
compared with olanzapine-only treatment, while a betahistine and reboxetine
combination treatment produced a two-fold larger weight attenuating effect, compared
with reboxetine only combination (Poyurovsky et al., 2013).

Using the established rat model of olanzapine-induced weight gain, our previous study
found that the short-term (2 weeks) co-treatment of O+B was effective to reduce (~45%)
the weight-gain side-effect induced by olanzapine in drug-naïve rats (Deng et al., 2012)
(Figure 2.5A). Food intake and feeding efficiency were also increased in rats treated
with olanzapine compared to controls. Although it was not significant during the two
weeks of treatment, rats co-administered with O+B consumed less food through the
treatment period, and had significantly lower feeding efficiency than rats treated with
olanzapine only (Figure 2.5B and C). However, no significant difference was observed
in water intake (Figure 2.5D). These results illustrated that olanzapine can induce body
weight gain, while co-treatment of O+B (2 weeks) may be used to reduce this sideeffect (Deng et al., 2012).

Behavioural tests revealed that locomotor activity was decreased in olanzapine and O+B
co-treatment compared with the control, while there was no difference between
olanzapine and co-treatment groups (Figure 2.6A and B). In contrast, betahistine only
treatment had no effect on locomotor activity compared with control (Figure 2.6A and
B). The rats treated with both olanzapine-only and co-treatment of O+B had lower
velocity compared with the control (Figure 2.6C) (Deng et al., 2012). These results
suggested that reduced activity partially contributed to the weight gain side-effect
induced by olanzapine. Co-treatment with betahistine did not improve locomotor
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activities decreased by olanzapine. This finding may be one possible explanation of why
betahistine can only partially improve olanzapine-induced weight gain (Deng et al.,
2012).

Figure 2.5 (A): Cumulative Body Weight Gain (g), (B): Cumulative Food Intake (g),
(C): Feeding Efficiency (weight gain/food intake), (D): Cumulative Water Intake (g) of
female Sprague Dawley rats treated with olanzapine (1 mg/kg, t.i.d.), betahistine (2.67
mg/kg, t.i.d.), co-treatment (O+B) or control (vehicle) for 14 days. **p<0.01 vs. control,
#p<0.05 vs. olanzapine (From Deng et al., 2012, reprinted with permission of SAGE).
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Figure 2.6 (A) Examples of locomotor activities from rats in the four treatment groups.
The locomotor activities in the open field test were traced using the Ethovision software.
(B) Total distance moved; (C) Velocity in the open field test. (O+B: co-treatment of
olanzapine and betahistine). **p<0.05, **p<0.01 vs. control (From Deng et al., 2012,
reprinted with permission of SAGE).

Overall, these findings further supported the important role of H1R in the olanzapineinduced weight gain side-effects, and had important implications for clinical trials using
betahistine to control olanzapine-induced obesity and its related metabolic disorders.
However, the exact mechanism underlying betahistine’s effect is not clear, which will
be addressed in this thesis.
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2.3 Rationales, aims and hypotheses
2.3.1 Rationales of this thesis
As reviewed above, a critical issue for schizophrenia patients is that control of their
symptoms, often requires a life-time treatment of antipsychotic drugs. SGAs such as
olanzapine are effective in treating the multiple domains of schizophrenia and are welltolerated by patients, with a lower propensity to induce EPS side-effects. It is generally
agreed that the pharmacological mechanisms of olanzapine therapeutics to treat
schizophrenia can mainly be attributed to its relatively higher antagonistic affinity to 5HT2AR and D2R.

Unfortunately, many SGAs such as olanzapine cause serious side-effects such as weight
gain, obesity, and other metabolic disorders. The management of these side-effects is
possibly even more expensive and disruptive for families and society than the
antipsychotic treatment itself (van Os and Kapur, 2009). Over the past decades, studies
have revealed that hypothalamic H1R and its downstream AMPK signalling,
hypothalamic neuropeptides NPY and POMC, as well as BAT UCP1 and PGC-1ɑ
signalling, may play key roles in the regulation of the olanzapine-induced weight gain
side-effects.

Since H1R antagonistic property is a main indicator for SGA-induced weight gain sideeffects, it is important to investigate the potential to control SGA-induced weight gain
by targeting H1R. Our previous study has shown that a short-term (2 weeks) cotreatment with betahistine (a histamine H1R agonist/H3R antagonist) was effective in
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preventing olanzapine-induced body weight gain in drug-naïve rats (Deng et al., 2012).
However the underlying mechanism is still waiting to be revealed.

Therefore, it is critical to determine, using our established rat model, whether cotreatment with betahistine ameliorates olanzapine-induced weight gain and hyperphagia
via modulating the hypothalamic HIR, AMPK, as well as NPY, AgRP, POMC and
CART (Han et al., 2008; Weston-Green et al., 2011; Deng et al., 2012). Furthermore,
under clinical conditions, many chronic schizophrenic patients may have already been
exposed to olanzapine treatment. Thus, it is also important to test whether betahistine
would be able to prevent weight gain in subjects with chronic repeated olanzapine
treatment. On the other hand, another key issue is to examine whether the co-treatment
with betahistine affects the therapeutic effects of olanzapine. One way to address this
issue is to examine the effects of co-treatment of olanzapine and betahistine on the key
receptors such as 5-HT2AR and D2R on the therapeutic effects of SGAs.

2.3.2 Aims
The general aim of this study is to investigate the effects and molecular mechanisms of
betahistine on reducing olanzapine-induced weight gain in rat models.

The specific aims of this research were to:
1.

Investigate whether co-treatment with betahistine is effective in reducing weight
gain-associated with olanzapine in both drug-naïve subjects and rats with chronic
and repeated exposure to olanzapine.
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2.

Reveal the molecular mechanisms underlying the effects of betahistine cotreatment in reducing olanzapine-induced weight gain side-effects in short-term
treatment/drug-naïve subjects and chronic treatment/drug-naïve rats.

3.

Examine whether betahistine co-treatment affects the key neurotransmission
binding sites for antipsychotic efficacy (e.g. dopaminergic and serotonergic
receptors) in the key brain regions, including the prefrontal cortex (PFC),
cingulate cortex (Cg), nucleus accumbens (NAc), and caudate putamen (CPu).

2.3.3 Hypotheses
1.

Co-treatment with betahistine will attenuate olanzapine-induced weight gain sideeffects by activating hypothalamic H1R-AMPK signalling, as well as activating
NPY, AgRP, POMC and CART neuropeptides in drug-naïve subjects. (Chapter 3)

2.

Betahistine co-treatment is effective to ameliorate olanzapine-induced body
weight gain, in subjects with chronic and repeated exposure to olanzapine through
modulating of H1R-pAMPK signalling, hypothalamic NPY, POMC, and BAT
UCP1, PGC-1ɑ activities. (Chapter 4)

3.

A short-term co-treatment with betahistine will not affect the key binding sites of
therapeutic effects of olanzapine in the dopamine and 5-HT transmissions in a
study of drug-naïve female rats. (Chapter 5)
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4.

Chronic co-treatment with betahistine will not affect the key binding sites for
therapeutic effects of olanzapine in dopamine and 5-HT transmission in rats with
repeated exposure of olanzapine. (Chapter 6)

Overall, in the thesis, all the above hypotheses have been tested in the established
animal model for olanzapine-induced weight gain (Han et al., 2008; Weston-Green et al.,
2011; Deng et al., 2012).
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CHAPTER 3
BETAHISTINE AMELIORATES OLANZAPINE-INDUCED
WEIGHT GAIN THROUGH MODULATION OF
HISTAMINERGIC, NPY AND AMPK PATHWAYS

Published in Psychoneuroendocrinology, 48, 77-86, Lian J, Huang X-F, Pai N and Deng
C, Betahistine ameliorates olanzapine-Induced weight gain through modulation of
histaminergic, NPY and AMPK Pathways, © 2014 Elsevier Inc; Reprinted with
permission from Elsevier Inc.
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CHAPTER 4
PREVENTING OLANZAPINE-INDUCED WEIGHT GAIN
USING BETAHISTINE: A STUDY IN A RAT MODEL WITH
CHRONIC OLANZAPINE TREATMENT

Published in PLoS ONE, 9(8): e104160, Lian J, Huang X-F, Pai N and Deng C,
Preventing olanzapine-induced weight gain using betahisitne: a study in a rat model
with chronic olanzapine treatment, Copyright © 2014 Lian et al. under the Creative
Commons Attribution Licence.

Jiamei Lian

65

Jiamei Lian

66

Jiamei Lian

67

Jiamei Lian

68

Jiamei Lian

69

Jiamei Lian

70

Jiamei Lian

71

Jiamei Lian

72

Jiamei Lian

73

Jiamei Lian

74

Jiamei Lian

75

Jiamei Lian

76

CHAPTER 5
EFFECTS OF OLANZAPINE AND BETAHISTINE COTREATMENT ON SEROTONIN TRANSPORTER, 5-HT2A
AND DOPAMINE D2 RECEPTOR BINDING DENSITY

Published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, 47,
62-68, Lian J, Huang X-F, Pai N and Deng C, Effects of olanzapine and betahistine cotreatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density, ©
2013 Elsevier Inc; Reprinted with permission from Elsevier Inc.
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CHAPTER 6
CHRONIC BETAHISTINE CO-TREATMENT REVERSES
OLANZAPINE’S EFFECTS ON DOPAMINE D2 BUT NOT
5-HT2A/2C BINDINGS IN RAT BRAINS

Published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, 56,
75-80, Lian J, Huang X-F, Pai N and Deng C, Chronic betahistine co-treatment reverses
olanzapine’s effects on dopamine D2 but not 5-HT2A/2C bindings in rat brains, © 2014
Elsevier Inc; Reprinted with permission from Elsevier Inc.
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CHAPTER 7
GENERAL DISCUSSION

7.1 Overall discussion
As discussed in earlier chapters, olanzapine, as the first line of SGAs, is widely
prescribed to treat schizophrenia and other mental disorders. However it is associated
with troublesome weight gain/obesity side-effects. Previous clinical trials have
revealed that, whether in first episode/antipsychotic-naïve patients or in chronic
schizophrenia patients with previous antipsychotic exposure, SGAs can cause
significant weight gain side-effects (Lieberman et al., 2005; Deng, 2013). In addition,
obesity and schizophrenic metabolic disorders associated with SGA treatments are the
leading causes of premature death. Therefore, it is extremely important to prevent and
treat weight gain/obesity induced by SGAs. This thesis investigated the effects of
betahistine to prevent and treat olanzapine-induced obesity and related mechanisms in
a female rat model. The following key outcomes have been achieved.

7.1.1 Further validated the animal model for olanzapine-induced weight gain
Previously, all studies in the animal model for olanzapine-induced weight gain used the
drug-naïve animals (Panariello et al., 2011; Van Der Zwaal et al., 2014). This thesis is
the first study showing that administration of olanzapine resulted in substantial weight
gain in both drug-naïve rats and those with chronically repeated treatment. In particular,
olanzapine treatment was observed to induce weight gain from week 1 and that weight
gain was maintained by continuing drug treatment (Chapter 4); this corresponded with
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the results of our and other laboratories using drug-naïve rats (Han et al., 2008; Fernø et
al., 2011; Deng et al., 2012). Interestingly, the weight loss effect was observed after a
withdrawal of olanzapine treatment in the current study (Chapter 4). Similarly, a
previous study demonstrated that withdrawal of oral olanzapine treatment caused weight
loss (Goudie et al., 2002). The weight loss during the drug withdrawal period is largely
due to the reduction of food intake and feeding efficiency. This is the first study to
reveal that, importantly, re-induction of olanzapine treatment caused significant weight
gain in rats (Chapter 4). Thus, these findings mimic the clinical observation that
olanzapine also caused significant weight gain in chronic schizophrenia patients with
repeated exposure to SGAs (Lieberman et al., 2005; Maayan et al., 2010). Therefore,
this thesis further validated the animal models mimicked olanzapine-induced body
weight gain side-effects in drug-naïve and chronic patients.

7.1.2 Proved the efficacy of co-treatment with betahistine in reducing olanzapineinduced weight gain in both drug-naïve rats and those with chronic repeated
olanzapine administration
The present study demonstrated that short-term (2 weeks) co-treatment with betahistine
partially reduced olanzapine-induced weight gain side-effects in drug-naïve rats
(Chapter 3). The result corresponded with short-term clinical trials in which cotreatment (6 weeks) with betahistine can cause less body weight gain compared to
olanzapine only in drug-naïve patients (Poyurovsky et al., 2005; Poyurovsky et al.,
2013). More importantly, the current chronic animal study (Chapter 4) revealed the
efficacy of chronic (5 weeks) co-treatment with betahistine in reducing the body weight
gain side-effects in rats with previous olanzapine exposure.
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In particular, the 2 weeks co-treatment with betahistine significantly prevented (-45%)
olanzapine-induced weight gain side-effects and reduced feeding efficiency in drugnaïve rats. Betahistine treatment alone had no effect on weight gain and food intake
(Deng et al., 2012) (Chapter 3). Similarly, chronic (5 weeks) co-administration with
betahistine significantly reduced (-51.4%) olanzapine-induced weight gain and feeding
efficiency in rats with previous olanzapine exposure (Chapter 4). Therefore, cotreatment with betahistine is effective to control olanzapine-induced weight gain in both
drug-naïve and chronic/repeat treatment rats. These results provided strong supports for
further clinical trials to improve olanzapine-induced obesity side-effects using
betahistine co-treatment in both drug-naïve and repeatedly treated subjects.

Although the dosage of betahistine used in the chronic animal study was higher than in
the short-term drug-naïve study (9.6 mg/kg vs. 2.67 mg/kg), both of them led to similar
effects on body weight gain reduction (about 50%), which suggested that betahistine has
no dosage dependent effects in reducing olanzapine-induced weight gain. Further study
is needed to examine whether the lower dosage (2.67 mg/kg) is also effective in
reducing weight gain in chronic/repeated olanzapine treatment conditions.

7.1.3 Revealed the mechanisms underlying effects of betahistine co-treatment on
reducing weight gain/obesity side-effects induced by olanzapine
The current studies (Chapters 3 and 4) provide evidence of the mechanisms underlying
the effects of co-treatment with betahistine in ameliorating olanzapine-induced weight
gain in female rat models. Corresponding with the previous findings in our and other
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laboratories, in which both the short term/drug-naïve and chronic/repeated studies
demonstrated that the regulation of olanzapine-induced weight gain may occur through
the upregulation of hypothalamic H1R-AMPKɑ signalling, and NPY levels,
accompanied by downregulation of POMC mRNA expression (Kim et al., 2007;
Meltzer, 2007; Deng et al., 2010; Fernø et al., 2011; Sezlev et al., 2013; He et al., 2014;
Skrede et al., 2014; Zhang et al., 2014a). In addition, this study revealed that the
expression of BAT UCP1 and PGC-1ɑ protein levels (biomarkers of thermogenesis) are
reduced by chronic olanzapine treatment (Chapter 4); this confirmed their roles in the
decreased energy expenditure and increased weight gain and feeding efficiency induced
by chronic treatment with olanzapine (Stefanidis et al., 2008; Zhang et al., 2014b)
(Chapters 3 and 4, Figure 2.3).

On the other hand, it was proven by the present short-term/drug-naïve and
chronic/repeated animal studies that co-treatment with betahistine attenuates
hypothalamic H1R and associated pathways in controlling olanzapine-induced weightgain. To our knowledge, this thesis is the first study to systematically investigate the
effects of olanzapine and betahistine co-treatment on hypothalamic H1R expression in
the rat brain using both drug-naïve and chronic animal models. This finding was
confirmed by a recent report from our laboratory that acute ICV injection of FMPH (an
H1R agonist) reduced olanzapine-induced hyperphagia (He et al., 2014). Give that
betahistine (also an H3R antagonist) can increase histamine release by blocking
presynaptic H3 autoreceptors, betahistine enhances its direct agonistic effects on H1R
receptors (Deng et al., 2012) (Chapter 2, Figure 2.4).
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Both the short-term and chronic studies have proven that the H1R-AMPKɑ signalling
pathway is elevated by olanzapine, which is reversed by co-treatment with betahistine
(Chapters 3 and 4). Furthermore, it is important the AMPKɑ/pAMPKɑ changes are
correlated with the changes in body weight gain, hyperphagia and feeding efficiency.
Since acute ICV injection of FMPH significantly reduced the olanzapine-induced
enhanced AMPKɑ levels (He et al., 2014), the effect of co-treatment with betahistine in
reversing AMPKɑ/pAMPKɑ signalling is through its activating H1Rs.

Moreover, AMPK phosphorylation could be promoted by stimulating the orexigenic
hormones such as NPY and AgRP (Lopez et al., 2008). It was revealed in Chapter 3 (2
weeks animal study) that co-treatment with betahistine attenuates the elevated
hypothalamic NPY mRNA expression induced by olanzapine. Since there are synaptic
interactions between NPY afferents and histaminergic neurons, and the H3R antagonist
suppresses NPY induced feeding (Itoh et al., 1999), it is possible that co-treatment with
betahistine may activate histamine H3R to inhibit olanzapine-induced hyperphagia by
suppressing NPY.

Although the current studies reported that olanzapine decreases the POMC mRNA
expression, it was not reversed by co-treatment with betahistine, which indicates that
betahistine reduction of olanzapine-induced weight gain was not via the POMC
pathway (Chapters 3 and 4). This result was consistent with previous reports that
hypothalamic H1R is independent of the POMC-melanocortin 4 receptor pathway in
regulation of food intake and body weight (Yoshimatsu, 2006); instead hypothalamic
POMC neurons, are regulated by 5-HT2CR as discussed in Chapter 2.
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The present chronic study also showed that BAT UCP1 and PGC-1ɑ levels are reduced
by chronic olanzapine treatment, and this reduction is reversed by chronic co-treatment
of O+B (Chapter 4). The results illustrated that the two biomarkers of thermogenesis
involved in the decreased energy expenditure and increased weight gain induced by
chronic olanzapine treatment, are reversed by co-treatment with betahistine.
Furthermore, this study also observed that negative correlation between hypothalamic
pAMPKɑ, and BAT UCP1 and PGC-1ɑ levels, which is in line with the previous report
about hypothalamic AMPK modulating BAT thermogenesis, and UCP1 and PGC-1ɑ
expressions (Lopez et al., 2010; Morrison et al., 2014; Wan et al., 2014; Zhang et al.,
2014b). Therefore, co-treatment with betahistine may regulate BAT UCP1 and PGC-1ɑ
via the hypothalamic H1R and pAMPKɑ pathway.

To sum up, this study demonstrated the mechanisms of co-treatment with betahistine in
reducing olanzapine-induced body weight gain via modulation of the hypothalamic
H1R-AMPKɑ, NPY, and BAT UCP1-PGC-1α pathways. Understanding the mechanisms
of betahistine in the prevention and treatment of olanzapine-induced obesity throughout
these signalling pathways will potentially lead to a new treatment strategy for
schizophrenia and highlight the need for the development of more effective
antipsychotic drugs with fewer side-effects.

7.1.4 Provides evidence that co-treatment with betahistine does not affect
therapeutic efficacy of olanzapine
As discussed in Chapter 2, another key issue was whether co-treatment with betahistine
affects the therapeutic effects of olanzapine. The present studies investigated the effects
of olanzapine and betahistine co-treatment on the 5-HT2AR, 5-HT2CR, 5-HTT, and D2R
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bindings in the brain regions associated with the therapeutic efficacy of olanzapine,
including the PFC, NAcC, NAcS and Cg in both drug-naïve and chronic/repeated
olanzapine-treated rats (Chapters 5 and 6).

Corresponding with previous reports, the present studies demonstrated a significant
downregulation of 5-HT2AR binding density by olanzapine treatment in various brain
regions including the PFC, Cg, NAcC and NAcS (Tarazi et al., 2002; Kuroki et al.,
2008; Meltzer and Massey, 2011), which was not affected by the treatment durations (2
weeks vs. 5 weeks), or drug exposure experience (drug-naïve vs. re-exposure). These
results confirmed olanzapine’s therapeutic efficacy via binding to serotonergic 5-HT2AR
in these brain regions. More importantly, the current studies revealed that co-treatment
with O+B does not affect olanzapine’s effect on 5-HT2AR. Nor did betahistine-only
treatment affect 5-HT2AR binding.

In addition, 5-HT2CR is another target for the therapeutic effects of antipsychotics
(Reynolds et al., 2005). Consistent with the 5-HT2AR, previous studies reported that 5HT2CR was also downregulated by SGA treatment including olanzapine (Tarazi et al.,
2002). This present study revealed that both olanzapine-only and O+B co-treatment has
similar effects on downregulation of 5-HT2CR binding density in the PFC, Cg, NAcC
and NAcS, while betahistine-only has no significant effect on 5-HT2CR bindings. The
effect of co-treatment with betahistine on 5-HT2CR was only examined in the chronic
study; it may have a similar effect in the short-term treatments, although further studies
are necessary to confirm this.
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The 5-HTT gene polymorphism studies have revealed an association with responses to
the therapeutic effects of olanzapine and other SGAs (Bozina et al., 2007; Zhang and
Malhotra, 2011). To date, no study has investigated the direct effects of SGAs on 5HTT bindings. To my knowledge, this thesis is the first study to investigate the direct
effects of olanzapine-only and co-treatment with betahistine on 5-HTT bindings. In
terms of the 5-HTT bindings in the short-term treatment study (Chapter 5), both O+B
co-treatment and olanzapine-only treatment significantly attenuated 5-HTT bindings in
the SN and VTA of drug-naïve rats. Comparatively, the chronic study (Chapter 6)
demonstrated that the reduced 5-HTT binding density was observed in the PFC, Cg,
NAcC and NAcS in olanzapine-only treatment and in the Cg and NAcS by co-treatment
with betahistine. It is interesting to note that co-treatment with betahistine had a similar
effect on 5-HTT bindings compared with olanzapine-only treatment in both short term
treatment in drug-naïve subjects and chronic treatment in drug re-exposure rats,
although these changes occurred in different brain regions (Chapters 5 and 6). These
difference could be due to different treatment dosage (2.67 mg/kg, vs. 9.6 mg/kg),
treatment period (2 weeks vs. 5 weeks) or drug exposure experience (drug-naïve vs.
repeated); further studies are necessary to identify the mechanism that caused these
difference between the short-term/drug naïve and chronic/drug re-exposure treatment.

The different effects on D2R bindings have been observed in the short and chronic
treatment studies (Chapters 5 and 6). Specifically, both olanzapine and co-treatment of
O+B did not cause any significant changes in D2R bindings in all brain regions tested
after 2 weeks treatment. However, our chronic olanzapine treatment upregulated the
D2R binding levels in the Cg, NAcC, NAcS, and CPu; and this is consistent with a
previous report in which chronic treatment of olanzapine at a high dosage (5mg/kg/day
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via osmotic minipumps) enhanced D2R binding in the PFC, CPu, and NAc (Tarazi et al.,
2001). This D2R upregulation induced by antipsychotics may be the underlying
mechanisms for “dopaminergic supersensitivity” observed in clinics (Samaha et al.,
2007; Seeman, 2011); long-term/chronic treatment with antipsychotics caused enhanced
vulnerability to psychosis frequently observed after drug withdrawal (Samaha et al.,
2007). Furthermore, although there was lower risk of EPS associated with SGAs
compared with FGAs, the elevated D2R binding level in the CPu observed in the
chronic olanzapine treatment may partially explain its risk for the development of EPS,
which is in line with other reports (Tarazi et al., 2001). Furthermore, it is interesting that
chronic betahistine-only treatment at the higher dosage (9.6 mg/kg) significantly
decreased D2R binding in the NAc and CPu, while no change was observed in shortterm treatment at a lower dosage. This difference is possibly attributed to both the
difference in dosage and treatment duration (2.67 mg/kg for 2 weeks study vs. 9.6
mg/kg for 5 weeks study). It is important to note that olanzapine-elevated D2R binding
in the NAc was reversed by co-treatment with betahistine, which suggests that cotreatment with betahistine may also reduce “dopaminergic supersensitivity” to some
extent (see details in Chapter 6). This may provide clinical benefits for chronic
olanzapine-treatment in schizophrenia patients.

Overall, the series of binding experiments in both short-term/drug-naïve and
chronic/drug-repeated treatment subjects revealed the effects of olanzapine and/or
betahistine administrations on the 5-HT2AR, 5-HT2CR, 5-HTT and D2R bindings in the
brain regions involved in the therapeutic effects of antipsychotics (Kuroki et al., 2008).
Since both olanzapine-only and O+B co-treatment have similar effects in attenuating 5HT2AR, 5-HT2CR and 5-HTT levels, betahistine is a safe drug for co-administration with
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neurotransmission. Additionally, since chronic olanzapine co-treatment with betahistine
can reverse the elevated D2R binding caused by chronic olanzapine treatment, cotreatment with betahistine may improve therapeutic effects by preventing the
“dopaminergic supersensitivity” caused by chronic antipsychotic treatment.

7.2 Recommendations for further research
Based on the findings of this thesis, recommendations for further research are presented
as follows:
1) Olanzapine causes not only weight gain but also other metabolic side-effects
including dyslipidemia. In this thesis olanzapine-only treatment has been found to
increase white fat accumulation and liver fat accumulation (Chapters 3 and 4),
while betahistine co-treatment decreased white fat and liver fat accumulation
compared to the olanzapine only group (Chapter 4). Therefore, further study would
be interesting to determine whether O+B co-treatment could prevent or reverse
dyslipidemia caused by olanzapine treatment.

2) Although olanzapine is the first line of SGAs in the clinic, other SGAs with serious
metabolic side-effects, such as clozapine and risperidone, are also widely
prescribed to patients with schizophrenia and other mental disorders (Patel et al.,
2009). Since these SGAs also have a high H1R antagonist affinity, it would be
valuable to investigate whether betahistine co-treatment is also effective to reverse
the weight gain side-effects associated with these SGAs.
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3) One limitation of this study is that only one dosage of olanzapine (1 mg/kg, t.i.d.,
equivalent to 10 mg in humans) was administered in this study. Since olanzapine is
recommended to be prescribed at a range of 5-20 mg, further studies are also
important to test whether betahistine has the same effects in the animal model when
used as a co-treatment with various dosages of olanzapine.

4) Although, clinically, female patients have a much higher risk than males off SGAinduced weight gain side-effects (Gebhardt et al., 2009; Seeman, 2009; WestonGreen et al., 2010; Treuer et al., 2011), SGAs do cause significant weight gain in
males. This thesis used a female rat model for olanzapine-induced weight gain,
since it is well established and validated in our and other laboratories (Goudie et al.,
2002; Choi et al., 2007; Weston-Green et al., 2011; Deng et al., 2012). It is
important to extend this study to the male rat model. For example, several studies
reported the male rat model for olanzapine-induced weight gain could be
established under special feeding conditions with high carbohydrate/medium
fat/low protein (45%/31%/14%) diets (Minet-Ringuet et al., 2006b; Shobo et al.,
2011). Therefore, given that olanzapine-induced weight gain/obesity occurs in
female and male patients, it is important to test in the male model whether using cotreatment of betahistine and olanzapine is effective to ameliorate olanzapineinduced body weight gain side-effects.

5) The results of this project (presented in Chapters 3 and 4) showed that co-treatment
with betahistine partially ameliorates olanzapine-induced side-effects via regulation
of the hypothalamic H1R level and related signalling pathways. Since other brain
regions such as the dorsal vague complex in the brain stem are also involved in
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body weight regulation (Deng et al., 2007; Weston-Green et al., 2008), it is
necessary to investigate whether co-treatment with betahistine has similar effects in
these brain regions, and their contributions to control SGA-induced weight gain
side-effects.

6) AMPK is composed of 3 subunits with various isoforms, including the catalytic
AMPKɑ (ɑ1, ɑ2), and non-catalytic AMPKβ (β1, β2) and AMPKγ (γ1, γ2, γ3)
(Moffat and Ellen Harper, 2010). Furthermore, a study revealed the crucial
association between polymorphism in AMPK subunit genes and olanzapineinduced weight gain side-effects (Souza et al., 2012). Due to the limitation of small
amount of samples (i.e. hypothalamic Arc), in this study, only AMPKɑ was
investigated (Chapters 3 and 4). Therefore, it is also important to reveal whether cotreatment of O+B has different effects on the various AMPKɑ subunits and
isoforms.

7) Olanzapine-only treatment had no effect on D2R binding density after 2 weeks’ of
drug treatment (Chapter 5), however it led to enhanced D2R binding density after
chronic treatment (Chapter 6). It was demonstrated that the elevated D2High
receptors were responsible for psychotic symptoms, which is reversed by
antipsychotic treatments, while long term antipsychotics can further enhance
dopamine supersensitivity in patients (Seeman, 2011). It has been reported that 9day olanzapine treatment led to a 2 fold increase in the proportion of D2High
receptors (Seeman, 2011). Therefore, it is important to investigate whether
olanzapine-only and co-treatment with betahistine affect the expression of D2High
receptors.
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8) This PhD research (both short-term and chronic animal studies) has found that cotreatment of olanzapine and betahistine can significantly reduce olanzapine-induced
weight gain, and revealed the underlying neuroendocrinological mechanisms in
animal models. Therefore, this study provides solid evidence to support clinical
trials to further investigate the effect of co-treatment with betahistine for
ameliorating the body weight gain/obesity side-effects in schizophrenia patients
with both acute/drug-naïve and chronic/repeated antipsychotic treatment.

7.3 Conclusion
To sum up, this PhD study has shown that co-treatment with betahistine can partially
reverse the olanzapine-induced body weight gain side-effects via attenuating food intake
and/or feeding efficiency in both short term/drug-naïve and chronic/drug-repeated
female rat models. Furthermore, these studies revealed the mechanisms of co-treatment
with betahistine on ameliorating olanzapine-induced weight gain side-effects, which are
modulated through hypothalamic H1R-AMPKɑ signalling and neuropeptides including
the orexigenic NPY pathway, as well as the BAT UCP1-PGC-1ɑ pathways modulating
thermogenesis. Therefore, these results not only confirm the importance of these
pathways in SGA-induced weight gain/obesity side-effects, but also implicate the
pathways as promising targets for pharmacological intervention to reduce the SGAinduced weight gain.

On the other hand, the present studies provide the first evidence to show that cotreatment with betahistine does not affect the key receptor binding sites for the
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therapeutic efficacy of olanzapine at serotonergic 5-HT2AR, 5-HT2CR and 5-HTT; this
indicates that co-treatment with betahistine does not affect olanzapine’s action on 5-HT
neurotransmissions in the relevant brain nuclei associated with antipsychotic therapeutic
effects. In addition, chronic betahistine treatment significantly reversed D2R biding
density enhanced by olanzapine, which suggests further investigations into whether cotreatment with betahistine could improve the efficacy of olanzapine by preventing the
“dopaminergic supersensitivity” caused by chronic antipsychotic treatment.

Last but not least, in conjunction with previous preclinical and clinical trials in drugnaïve subjects (Poyurovsky et al., 2005; Deng et al., 2012; Poyurovsky et al., 2013), the
results from this study further supports a clinical trial to investigate the effects of cotreatment with betahistine on reducing olanzapine-induced weight gain side-effects in
schizophrenia patients with chronic and repeated antipsychotic treatment.
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APPENIDCES

Appendix A-Chapter 2 Supplementary
Supplement 1 Copyright permission from SAGE
The Figures 2.4, 2.5 and 2.6 in the Chapter 2 were reprinted from my previous
publication “Deng C, Lian J, Pai N, Huang X-F (2012). Reducing olanzapine-induced
weight gain side-effect by betahistine: a study in the rat model. Journal of
Psychopharmacology 26 (9) 1271-1279”. As one of the authors of this paper, I was
permitted to re-use these figures in my thesis by the publisher SAGE (see page 107).
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Supplement 2 Copyright permission from Elsevier
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Supplement 2 Copyright permission from Elsevier
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